[{"id":"adrian-ochsenbein","name":"Adrian Ochsenbein","tldr":"Bern medical oncology chief whose lab targets leukaemia stem cells and CD70 signalling.","route":"/people/adrian-ochsenbein/","kind":"person","round":true,"avatar":"person","sub":"Director UCI; Chief Physician, Medical Oncology · Inselspital, Bern University Hospital / University Cancer Center Inselspital","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia","Chronic myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"akifumi-takaori","name":"Akifumi Takaori","tldr":"Hematologist who directs Kyoto University Hospital, one of Japan's leading academic medical centres.","route":"/people/akifumi-takaori/","kind":"person","round":true,"avatar":"person","sub":"Director of Kyoto University Hospital · Kyoto University Hospital","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hematology","href":"/tagged/hematology/","tip":"Every record tagged hematology."},{"label":"leukemia","href":"/tagged/leukemia/","tip":"Every record tagged leukemia."}]},"sortKeys":{"year":0}},{"id":"alexandre-chan","name":"Alexandre Chan","tldr":"Oncology pharmacist-scientist at UC Irvine and President of MASCC, the multinational society for supportive care in cancer, known for research on cancer-related cognitive impairment.","route":"/people/alexandre-chan/","kind":"person","round":true,"avatar":"person","sub":"President · Multinational Association of Supportive Care in Cancer","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"supportive care","href":"/tagged/supportive-care/","tip":"Every record tagged supportive care."},{"label":"survivorship","href":"/tagged/survivorship/","tip":"Every record tagged survivorship."}]},"sortKeys":{"year":0}},{"id":"alexis-cortot","name":"Alexis Cortot","tldr":"Lille pulmonologist and thoracic oncologist who presides over the IFCT, France's academic lung cancer trials group.","route":"/people/alexis-cortot/","kind":"person","round":true,"avatar":"person","sub":"President · Intergroupe Francophone de Cancérologie Thoracique","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"alfredo-addeo","name":"Alfredo Addeo","tldr":"Thoracic oncologist who heads the Oncology Division at Geneva University Hospitals.","route":"/people/alfredo-addeo/","kind":"person","round":true,"avatar":"person","sub":"Head of Division, Oncology · Geneva University Hospitals (HUG)","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer","Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"ali-taher","name":"Ali Taher","tldr":"Physician who directs the Naef K. Basile Cancer Institute, the multidisciplinary cancer centre of the American University of Beirut Medical Center in Lebanon.","route":"/people/ali-taher/","kind":"person","round":true,"avatar":"person","sub":"Director, Naef K. Basile Cancer Institute, American University of Beirut Medical Center · American University of Beirut Medical Center / Naef K. Basile Cancer Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"ander-urruticoechea","name":"Ander Urruticoechea","tldr":"Medical oncologist from Gipuzkoa who became President of GEICAM, Spain's academic breast cancer research group, in 2025 on the retirement of its founder Miguel Martín.","route":"/people/ander-urruticoechea/","kind":"person","round":true,"avatar":"person","sub":"Presidente (President) of GEICAM, the Spanish Breast Cancer Group · GEICAM Spanish Breast Cancer Group","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"professional-society","href":"/tagged/professional-society/","tip":"Every record tagged professional-society."}]},"sortKeys":{"year":0}},{"id":"andrzej-kawecki","name":"Andrzej Kawecki","tldr":"Radiation oncologist specialising in head and neck cancer who oversees clinical affairs at Poland's National Research Institute of Oncology.","route":"/people/andrzej-kawecki/","kind":"person","round":true,"avatar":"person","sub":"Deputy Director for Clinical Affairs · Maria Skłodowska-Curie National Research Institute of Oncology","facets":{"kind":["Person"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."}]},"sortKeys":{"year":0}},{"id":"ane-gerda-eriksson","name":"Ane Gerda Eriksson","tldr":"Oslo gynaecological oncology surgeon at the Norwegian Radium Hospital and President-Elect of ESGO.","route":"/people/ane-gerda-eriksson/","kind":"person","round":true,"avatar":"person","sub":"President-Elect · European Society of Gynaecological Oncology","facets":{"kind":["Person"],"cancers":["Endometrial cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gynaecological oncology","href":"/tagged/gynaecological-oncology/","tip":"Every record tagged gynaecological oncology."}]},"sortKeys":{"year":0}},{"id":"anna-sapino","name":"Anna Sapino","tldr":"Pathologist and Scientific Director of the Candiolo Cancer Institute (INOC), Piedmont's oncology IRCCS and an OECI-certified Comprehensive Cancer Centre.","route":"/people/anna-sapino/","kind":"person","round":true,"avatar":"person","sub":"Scientific Director · Istituto di Candiolo IRCCS (FPO)","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"pathology","href":"/tagged/pathology/","tip":"Every record tagged pathology."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."}]},"sortKeys":{"year":0}},{"id":"annika-auranen","name":"Annika Auranen","tldr":"Chief physician who directs Tays Cancer Centre in Tampere and the FICAN Mid regional cancer centre for central Finland.","route":"/people/annika-auranen/","kind":"person","round":true,"avatar":"person","sub":"Director and Chief Physician, Tays Cancer Centre · Tays Cancer Centre, Tampere University Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"anthony-chan","name":"Anthony T. C. Chan","tldr":"Leading nasopharyngeal carcinoma researcher who directs the Hong Kong Cancer Institute at CUHK.","route":"/people/anthony-chan/","kind":"person","round":true,"avatar":"person","sub":"Li Shu Fan Medical Foundation Professor of Clinical Oncology; Director, Hong Kong Cancer Institute · Prince of Wales Hospital / Chinese University of Hong Kong","facets":{"kind":["Person"],"cancers":["Nasopharyngeal carcinoma","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"nasopharyngeal cancer","href":"/tagged/nasopharyngeal-cancer/","tip":"Every record tagged nasopharyngeal cancer."},{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."}]},"sortKeys":{"year":0}},{"id":"antonio-cuneo","name":"Antonio Cuneo","tldr":"Ferrara haematologist and CLL expert who chairs GIMEMA's Scientific Committee.","route":"/people/antonio-cuneo/","kind":"person","round":true,"avatar":"person","sub":"President of the Scientific Committee · GIMEMA","facets":{"kind":["Person"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."}]},"sortKeys":{"year":0}},{"id":"antonio-gonzalez-martin","name":"Antonio González-Martín","tldr":"Gynaecological medical oncologist directing the Cancer Center Clínica Universidad de Navarra; led the PRIMA trial of niraparib maintenance in ovarian cancer.","route":"/people/antonio-gonzalez-martin/","kind":"person","round":true,"avatar":"person","sub":"Director, Cancer Center Clínica Universidad de Navarra · Cancer Center Clínica Universidad de Navarra / CIMA","facets":{"kind":["Person"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"ovarian cancer","href":"/tagged/ovarian-cancer/","tip":"Every record tagged ovarian cancer."},{"label":"gynaecological oncology","href":"/tagged/gynaecological-oncology/","tip":"Every record tagged gynaecological oncology."}]},"sortKeys":{"year":0}},{"id":"antonio-rosato","name":"Antonio Rosato","tldr":"Immunologist and Scientific Director of the Istituto Oncologico Veneto, leading its translational cancer research.","route":"/people/antonio-rosato/","kind":"person","round":true,"avatar":"person","sub":"Scientific Director · Istituto Oncologico Veneto IRCCS","facets":{"kind":["Person"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"armando-santoro","name":"Armando Santoro","tldr":"Veteran Italian medical oncologist who leads oncology and haematology at Humanitas and has co-authored major trials in lymphoma, liver cancer and novel targeted drugs.","route":"/people/armando-santoro/","kind":"person","round":true,"avatar":"person","sub":"Head of the Medical Oncology and Hematology Unit; Full Professor of Medical Oncology, Humanitas University · IRCCS Humanitas Research Hospital","facets":{"kind":["Person"],"cancers":["Hodgkin lymphoma","Diffuse large B-cell lymphoma","Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."},{"label":"drug development","href":"/tagged/drug-development/","tip":"Every record tagged drug development."}]},"sortKeys":{"year":0}},{"id":"atiporn-ingsathit","name":"Atiporn Ingsathit","tldr":"Physician who directs Ramathibodi Hospital, the university hospital of the Faculty of Medicine Ramathibodi Hospital at Mahidol University in Bangkok.","route":"/people/atiporn-ingsathit/","kind":"person","round":true,"avatar":"person","sub":"Director of Ramathibodi Hospital · Ramathibodi Hospital, Mahidol University","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"university-hospital","href":"/tagged/university-hospital/","tip":"Every record tagged university-hospital."}]},"sortKeys":{"year":0}},{"id":"axel-behrens","name":"Axel Behrens","tldr":"Cancer biologist who directs the Cancer Research UK Convergence Science Centre, the joint Institute of Cancer Research and Imperial College London programme bringing engineering and physical sciences into cancer research.","route":"/people/axel-behrens/","kind":"person","round":true,"avatar":"person","sub":"Director, Cancer Research UK Convergence Science Centre · Cancer Research UK Convergence Science Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"barbara-jereczek-fossa","name":"Barbara Jereczek-Fossa","tldr":"Milan radiation oncologist leading ESTRO, Europe's radiotherapy and oncology society.","route":"/people/barbara-jereczek-fossa/","kind":"person","round":true,"avatar":"person","sub":"President · European Society for Radiotherapy and Oncology","facets":{"kind":["Person"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"prostate cancer","href":"/tagged/prostate-cancer/","tip":"Every record tagged prostate cancer."}]},"sortKeys":{"year":0}},{"id":"benjamin-kasenda","name":"Benjamin Kasenda","tldr":"Basel haematologist-oncologist who co-led phase 2 trials of high-dose chemotherapy and autologous transplant in primary CNS lymphoma.","route":"/people/benjamin-kasenda/","kind":"person","round":true,"avatar":"person","sub":"Senior Physician, Medical Oncology and Haematology (Tumour Centre) · University Hospital Basel / Tumour Centre","facets":{"kind":["Person"],"cancers":["Primary CNS lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Primary CNS lymphoma","href":"/cancers/primary-cns-lymphoma/","tip":"Primary CNS lymphoma is a lymphoma confined to the brain, eyes and spinal fluid. Unlike most brain tumours it is chemo-sensitive: high-dose methotrexate-based treatment cures a substantial minority, and consolidation with a stem-cell transplant has replaced whole-brain radiation for the fit."}],"tags":[{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"benjamin-kile","name":"Benjamin Kile","tldr":"Blood cell molecular biologist who has led Sydney's Garvan Institute of Medical Research since 2023, sharpening its focus on genomics, immunology and cancer.","route":"/people/benjamin-kile/","kind":"person","round":true,"avatar":"person","sub":"Executive Director · Garvan Institute of Medical Research / Kinghorn Cancer Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"genomics","href":"/tagged/genomics/","tip":"Every record tagged genomics."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"biju-george","name":"Biju George","tldr":"Physician who serves as Director of Christian Medical College, Vellore, the not-for-profit teaching hospital and medical school in Tamil Nadu, India.","route":"/people/biju-george/","kind":"person","round":true,"avatar":"person","sub":"Director, Christian Medical College, Vellore · Christian Medical College, Vellore","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"boris-pasche","name":"Boris C. Pasche","tldr":"Oncologist who leads the Barbara Ann Karmanos Cancer Institute in Detroit as President and CEO and chairs the Department of Oncology at Wayne State University.","route":"/people/boris-pasche/","kind":"person","round":true,"avatar":"person","sub":"President and Chief Executive Officer, Barbara Ann Karmanos Cancer Institute · Barbara Ann Karmanos Cancer Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"bradley-cairns","name":"Bradley Cairns","tldr":"Epigenetics researcher who became CEO of Huntsman Cancer Institute at the University of Utah in September 2025.","route":"/people/bradley-cairns/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer · Huntsman Cancer Institute, University of Utah","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"epigenetics","href":"/tagged/epigenetics/","tip":"Every record tagged epigenetics."}]},"sortKeys":{"year":0}},{"id":"brandon-wainwright","name":"Brandon Wainwright","tldr":"Geneticist known for work on the genetic drivers of childhood brain cancer who became Director and CEO of QIMR Berghofer, a leading Australian medical research institute, in 2026.","route":"/people/brandon-wainwright/","kind":"person","round":true,"avatar":"person","sub":"Director and CEO of QIMR Berghofer Medical Research Institute · QIMR Berghofer Medical Research Institute","facets":{"kind":["Person"],"cancers":["Medulloblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Medulloblastoma","href":"/cancers/medulloblastoma/","tip":"Medulloblastoma is the most common malignant childhood brain tumour, arising in the cerebellum. Surgery, radiation to the whole brain and spine, and chemotherapy cure about 70%, at a heavy cost to thinking and growth; treatment is now being tailored to four molecular subgroups so that the low-risk children get less."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"genetics","href":"/tagged/genetics/","tip":"Every record tagged genetics."},{"label":"paediatric-oncology","href":"/tagged/paediatric-oncology/","tip":"Every record tagged paediatric-oncology."}]},"sortKeys":{"year":0}},{"id":"brasil-silva-neto","name":"Brasil Silva Neto","tldr":"Urologist who has served as President of Hospital de Clínicas de Porto Alegre, a leading Brazilian university hospital, since 2024.","route":"/people/brasil-silva-neto/","kind":"person","round":true,"avatar":"person","sub":"President · Hospital de Clínicas de Porto Alegre","facets":{"kind":["Person"],"cancers":["Prostate cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"urology","href":"/tagged/urology/","tip":"Every record tagged urology."},{"label":"prostate cancer","href":"/tagged/prostate-cancer/","tip":"Every record tagged prostate cancer."}]},"sortKeys":{"year":0}},{"id":"brian-huntly","name":"Brian Huntly","tldr":"Cambridge haematologist and EHA President Elect whose laboratory studies how epigenetic regulators drive leukaemia and how they can be targeted.","route":"/people/brian-huntly/","kind":"person","round":true,"avatar":"person","sub":"President Elect · European Hematology Association","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."}]},"sortKeys":{"year":0}},{"id":"bruno-sangro","name":"Bruno Sangro","tldr":"Hepatologist at Clínica Universidad de Navarra and a leading international investigator in liver cancer systemic therapy and radioembolisation.","route":"/people/bruno-sangro/","kind":"person","round":true,"avatar":"person","sub":"Translational Research lead, Executive Committee · Cancer Center Clínica Universidad de Navarra / CIMA","facets":{"kind":["Person"],"cancers":["Hepatocellular carcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[{"label":"liver cancer","href":"/tagged/liver-cancer/","tip":"Every record tagged liver cancer."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"zhou-caicun","name":"Caicun Zhou","tldr":"Principal investigator of HARMONi-2, the trial where ivonescimab beat pembrolizumab head-to-head, and of the first EGFR-TKI phase 3 in Chinese patients.","route":"/people/zhou-caicun/","kind":"person","round":true,"avatar":"person","sub":"Professor of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University; President, IASLC (2025-2027) · Shanghai Pulmonary Hospital","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."}]},"sortKeys":{"year":0}},{"id":"carla-van-gils","name":"Carla van Gils","tldr":"Cancer epidemiologist who co-leads KWF, the Dutch Cancer Society, the Netherlands' largest charitable funder of cancer research.","route":"/people/carla-van-gils/","kind":"person","round":true,"avatar":"person","sub":"Bestuurder (Executive Director) of KWF Kankerbestrijding, jointly with Dorine Manson · KWF Dutch Cancer Society","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"epidemiology","href":"/tagged/epidemiology/","tip":"Every record tagged epidemiology."},{"label":"research-funding","href":"/tagged/research-funding/","tip":"Every record tagged research-funding."}]},"sortKeys":{"year":0}},{"id":"chak-sing-lau","name":"Chak-sing Lau","tldr":"Rheumatologist who is Dean of Medicine at the University of Hong Kong, the academic partner of Queen Mary Hospital, and formerly chief of the hospital's Department of Medicine.","route":"/people/chak-sing-lau/","kind":"person","round":true,"avatar":"person","sub":"Dean of Medicine, LKS Faculty of Medicine, The University of Hong Kong · Queen Mary Hospital / University of Hong Kong","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"academic-medicine","href":"/tagged/academic-medicine/","tip":"Every record tagged academic-medicine."}]},"sortKeys":{"year":0}},{"id":"charlie-gourley","name":"Charlie Gourley","tldr":"Edinburgh medical oncologist and ovarian cancer researcher who is Clinical Director of the CRUK Scotland Centre.","route":"/people/charlie-gourley/","kind":"person","round":true,"avatar":"person","sub":"Clinical Director, CRUK Scotland Centre · Edinburgh Cancer Centre / CRUK Scotland Centre","facets":{"kind":["Person"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"ovarian cancer","href":"/tagged/ovarian-cancer/","tip":"Every record tagged ovarian cancer."}]},"sortKeys":{"year":0}},{"id":"chee-cheng-ean","name":"Chee Cheng Ean","tldr":"Medical oncologist who leads Singapore's National University Cancer Institute (NCIS), the country's public cancer centre for adults and children.","route":"/people/chee-cheng-ean/","kind":"person","round":true,"avatar":"person","sub":"Executive Director · National University Hospital / National University Cancer Institute, Singapore","facets":{"kind":["Person"],"cancers":["Colorectal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"medical oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical oncology."},{"label":"gastrointestinal cancer","href":"/tagged/gastrointestinal-cancer/","tip":"Every record tagged gastrointestinal cancer."}]},"sortKeys":{"year":0}},{"id":"chen-chien-tzung","name":"Chen Chien-Tzung","tldr":"Plastic and reconstructive surgeon who leads Linkou Chang Gung Memorial Hospital, the flagship medical centre of Taiwan's Chang Gung hospital system.","route":"/people/chen-chien-tzung/","kind":"person","round":true,"avatar":"person","sub":"Superintendent of Linkou Chang Gung Memorial Hospital · Chang Gung Memorial Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"chris-hillis","name":"Chris Hillis","tldr":"Blood cancer specialist who leads the Juravinski Cancer Centre, one of Ontario's largest integrated cancer programmes, as Vice President of Oncology.","route":"/people/chris-hillis/","kind":"person","round":true,"avatar":"person","sub":"Vice President, Oncology and Site Executive, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences · Juravinski Cancer Centre / Escarpment Cancer Research Institute","facets":{"kind":["Person"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"christian-brandts","name":"Christian Brandts","tldr":"Haematologist-oncologist who is Managing Director of the University Cancer Center Frankfurt.","route":"/people/christian-brandts/","kind":"person","round":true,"avatar":"person","sub":"Director, UCT Frankfurt (Geschäftsführender Direktor) · University Cancer Center Frankfurt (UCT)","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"precision oncology","href":"/tagged/precision-oncology/","tip":"Every record tagged precision oncology."}]},"sortKeys":{"year":0}},{"id":"christian-capitini","name":"Christian Capitini","tldr":"Physician who directs the University of Wisconsin Carbone Cancer Center, the NCI-designated comprehensive cancer centre in Madison.","route":"/people/christian-capitini/","kind":"person","round":true,"avatar":"person","sub":"Director, University of Wisconsin Carbone Cancer Center · University of Wisconsin Carbone Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"christian-singer","name":"Christian Singer","tldr":"Gynaecological oncologist at the Medical University of Vienna and ABCSG Vice-President, known for work on breast cancer and hereditary cancer risk.","route":"/people/christian-singer/","kind":"person","round":true,"avatar":"person","sub":"Vice-President · Austrian Breast & Colorectal Cancer Study Group","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"hereditary cancer","href":"/tagged/hereditary-cancer/","tip":"Every record tagged hereditary cancer."}]},"sortKeys":{"year":0}},{"id":"christiane-pott","name":"Christiane Pott","tldr":"Kiel professor of medicine who serves as President of the German Lymphoma Alliance, the umbrella body for German lymphoma study groups, alongside co-president Georg Lenz.","route":"/people/christiane-pott/","kind":"person","round":true,"avatar":"person","sub":"President (Praesidentin) of the German Lymphoma Alliance · German Lymphoma Alliance","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"cooperative-group","href":"/tagged/cooperative-group/","tip":"Every record tagged cooperative-group."}]},"sortKeys":{"year":0}},{"id":"christos-karapetis","name":"Christos Karapetis","tldr":"Australian medical oncologist whose landmark NEJM analysis showed KRAS mutation predicts lack of benefit from cetuximab in colorectal cancer.","route":"/people/christos-karapetis/","kind":"person","round":true,"avatar":"person","sub":"Board Director · Australasian Gastro-Intestinal Trials Group","facets":{"kind":["Person"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"colorectal cancer","href":"/tagged/colorectal-cancer/","tip":"Every record tagged colorectal cancer."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"d-wade-clapp","name":"D. Wade Clapp","tldr":"Paediatric haematologist-oncologist and National Academy of Medicine member who is Interim Director of the IU Simon Comprehensive Cancer Center in Indianapolis.","route":"/people/d-wade-clapp/","kind":"person","round":true,"avatar":"person","sub":"Interim Director, Indiana University Melvin and Bren Simon Comprehensive Cancer Center · Indiana University Melvin and Bren Simon Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"dan-theodorescu","name":"Dan Theodorescu","tldr":"Professor of urology and of cellular and molecular medicine who directs the University of Arizona Cancer Center, the NCI-designated cancer centre in Tucson.","route":"/people/dan-theodorescu/","kind":"person","round":true,"avatar":"person","sub":"Director, University of Arizona Cancer Center · University of Arizona Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"daniel-aebersold","name":"Daniel M. Aebersold","tldr":"Radiation oncologist who chairs the directorate of the University Cancer Center Inselspital in Bern.","route":"/people/daniel-aebersold/","kind":"person","round":true,"avatar":"person","sub":"Chair of the UCI Directorate; Chief Physician, Radiation Oncology · Inselspital, Bern University Hospital / University Cancer Center Inselspital","facets":{"kind":["Person"],"cancers":["Head and neck squamous cell carcinoma","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."}]},"sortKeys":{"year":0}},{"id":"dario-altieri","name":"Dario C. Altieri","tldr":"Cancer biologist who has been President and CEO of The Wistar Institute in Philadelphia since 2015 and directs its NCI-designated Ellen and Ronald Caplan Cancer Center.","route":"/people/dario-altieri/","kind":"person","round":true,"avatar":"person","sub":"President and Chief Executive Officer, The Wistar Institute; Director, Ellen and Ronald Caplan Cancer Center · The Wistar Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"david-baker","name":"David Baker","tldr":"Nobel laureate biochemist who founded and directs the Institute for Protein Design, which builds new proteins for medicine including cancer therapeutics.","route":"/people/david-baker/","kind":"person","logo":"/portraits/david-baker.jpg","round":true,"avatar":"person","sub":"Founder and Director of the Institute for Protein Design · Institute for Protein Design (University of Washington)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"protein-design","href":"/tagged/protein-design/","tip":"Every record tagged protein-design."},{"label":"drug-discovery","href":"/tagged/drug-discovery/","tip":"Every record tagged drug-discovery."}]},"sortKeys":{"year":0}},{"id":"david-fennelly","name":"David Fennelly","tldr":"Medical oncologist who is Clinical Director for Cancer Services at St Vincent's University Hospital and its UCD Cancer Centre in Dublin, Ireland's largest cancer care provider.","route":"/people/david-fennelly/","kind":"person","round":true,"avatar":"person","sub":"Clinical Director for Cancer Services, St Vincent's University Hospital and St Vincent's UCD Cancer Centre · St Vincent's University Hospital / UCD Cancer Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"david-planchard","name":"David Planchard","tldr":"Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer.","route":"/people/david-planchard/","kind":"person","round":true,"avatar":"person","sub":"Board member (Conseil d'Administration) · Intergroupe Francophone de Cancérologie Thoracique","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"targeted therapy","href":"/tagged/targeted-therapy/","tip":"Every record tagged targeted therapy."}]},"sortKeys":{"year":0}},{"id":"dearbhaile-collins","name":"Dearbhaile Collins","tldr":"Medical oncologist who leads cancer services at Cork University Hospital as Clinical Director, with a focus on gynaecological and thoracic cancers and early-phase trials.","route":"/people/dearbhaile-collins/","kind":"person","round":true,"avatar":"person","sub":"Clinical Director of Cancer Services and Consultant Medical Oncologist, Cork University Hospital · Cork University Hospital / UCC Cancer Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"derrick-haslem","name":"Derrick S. Haslem","tldr":"Medical oncologist who leads the oncology clinical programme across Intermountain Health's cancer centres in Utah and neighbouring states.","route":"/people/derrick-haslem/","kind":"person","round":true,"avatar":"person","sub":"Senior Medical Director of the Oncology Clinical Program, Intermountain Health · Intermountain Health Cancer Center","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"medical-oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical-oncology."},{"label":"tele-oncology","href":"/tagged/tele-oncology/","tip":"Every record tagged tele-oncology."}]},"sortKeys":{"year":0}},{"id":"diane-simeone","name":"Diane M. Simeone","tldr":"Pancreatic cancer surgeon-scientist who directs UC San Diego Moores Cancer Center, an NCI-designated comprehensive cancer center.","route":"/people/diane-simeone/","kind":"person","round":true,"avatar":"person","sub":"Director, Moores Cancer Center; Koman Family Presidential Director's Chair · UC San Diego Moores Cancer Center","facets":{"kind":["Person"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"pancreatic cancer","href":"/tagged/pancreatic-cancer/","tip":"Every record tagged pancreatic cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"diep-bao-tuan","name":"Diệp Bảo Tuấn","tldr":"Physician who directs Ho Chi Minh City Oncology Hospital, the main public cancer hospital serving southern Vietnam.","route":"/people/diep-bao-tuan/","kind":"person","round":true,"avatar":"person","sub":"Director (Giám đốc), Ho Chi Minh City Oncology Hospital · Ho Chi Minh City Oncology Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"dirk-schadendorf","name":"Dirk Schadendorf","tldr":"Melanoma expert who directs the West German Cancer Center at University Hospital Essen.","route":"/people/dirk-schadendorf/","kind":"person","round":true,"avatar":"person","sub":"Director WTZ Essen; Director, Department of Dermatology · West German Cancer Center (WTZ), University Hospital Essen","facets":{"kind":["Person"],"cancers":["Melanoma","Cutaneous squamous cell carcinoma","Merkel cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Cutaneous squamous cell carcinoma","href":"/cancers/cutaneous-scc/","tip":"Cutaneous squamous cell carcinoma is a sun-related skin cancer with over a million US cases a year, almost all cured by removing them. The 2 to 5% that grow deep or spread respond to PD-1 immunotherapy (cemiplimab, pembrolizumab), which is now also given after surgery in high-risk cases; transplant recipients cannot safely receive it."},{"label":"Merkel cell carcinoma","href":"/cancers/merkel-cell-carcinoma/","tip":"Merkel cell carcinoma is a rare, fast-growing skin cancer, usually caused by a common virus (Merkel cell polyomavirus) or by sun damage. It was almost untreatable once it spread; PD-1/PD-L1 immunotherapy now gives lasting responses in about half of patients."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"melanoma","href":"/tagged/melanoma/","tip":"Every record tagged melanoma."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"diwani-msemo","name":"Diwani Msemo","tldr":"Executive Director of the Ocean Road Cancer Institute, Tanzania's national cancer hospital in Dar es Salaam.","route":"/people/diwani-msemo/","kind":"person","round":true,"avatar":"person","sub":"Executive Director, Ocean Road Cancer Institute · Ocean Road Cancer Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"africa","href":"/tagged/africa/","tip":"Every record tagged africa."},{"label":"global-oncology","href":"/tagged/global-oncology/","tip":"Every record tagged global-oncology."}]},"sortKeys":{"year":0}},{"id":"dorraya-el-ashry","name":"Dorraya El-Ashry","tldr":"Breast cancer biologist and Chief Scientific Officer of the Breast Cancer Research Foundation, directing its global research grant portfolio.","route":"/people/dorraya-el-ashry/","kind":"person","round":true,"avatar":"person","sub":"Chief Scientific Officer · Breast Cancer Research Foundation","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."}]},"sortKeys":{"year":0}},{"id":"eli-sprecher","name":"Eli Sprecher","tldr":"Dermatologist and geneticist who has been chief executive of Tel Aviv Sourasky Medical Center, a major Israeli academic hospital, since 2024.","route":"/people/eli-sprecher/","kind":"person","logo":"/portraits/eli-sprecher.jpg","round":true,"avatar":"person","sub":"CEO, Tel Aviv Sourasky Medical Center (Ichilov) · Tel Aviv Sourasky Medical Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"dermatology","href":"/tagged/dermatology/","tip":"Every record tagged dermatology."},{"label":"genetics","href":"/tagged/genetics/","tip":"Every record tagged genetics."}]},"sortKeys":{"year":0}},{"id":"elisabeth-schorb","name":"Elisabeth Schorb","tldr":"Internal medicine oncologist who directs the Comprehensive Cancer Center Freiburg and heads its clinical trials unit.","route":"/people/elisabeth-schorb/","kind":"person","round":true,"avatar":"person","sub":"Director and Spokesperson of the Tumorzentrum Freiburg - CCCF · Comprehensive Cancer Center Freiburg (CCCF)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer-centre","href":"/tagged/cancer-centre/","tip":"Every record tagged cancer-centre."}]},"sortKeys":{"year":0}},{"id":"emmanuel-barranger","name":"Emmanuel Barranger","tldr":"Professor who runs the Centre Antoine Lacassagne, the regional cancer centre in Nice, as its Directeur Général.","route":"/people/emmanuel-barranger/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général of the Centre Antoine Lacassagne · Centre Antoine Lacassagne","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer-centre","href":"/tagged/cancer-centre/","tip":"Every record tagged cancer-centre."}]},"sortKeys":{"year":0}},{"id":"eva-ciruelos","name":"Eva Ciruelos","tldr":"Madrid breast oncologist and Vice President of the SOLTI breast cancer research group.","route":"/people/eva-ciruelos/","kind":"person","round":true,"avatar":"person","sub":"Vice President (Vicepresidenta) · SOLTI Cancer Research Group","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."}]},"sortKeys":{"year":0}},{"id":"farhat-abbas","name":"Farhat Abbas","tldr":"Urological surgeon who is Chief Executive Officer of the Aga Khan University Hospital and Health System in Pakistan, based at the Karachi teaching hospital.","route":"/people/farhat-abbas/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer, The Aga Khan University Hospital and Health System, Pakistan · Aga Khan University Hospital, Karachi","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"florian-greten","name":"Florian R. Greten","tldr":"Tumour biologist known for linking inflammation to cancer, directing the Georg-Speyer-Haus within UCT Frankfurt.","route":"/people/florian-greten/","kind":"person","logo":"/portraits/florian-greten.png","round":true,"avatar":"person","sub":"Director, Georg-Speyer-Haus (Institute for Tumor Biology and Experimental Therapy) · University Cancer Center Frankfurt (UCT)","facets":{"kind":["Person"],"cancers":["Colorectal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer biology","href":"/tagged/cancer-biology/","tip":"Every record tagged cancer biology."},{"label":"colorectal cancer","href":"/tagged/colorectal-cancer/","tip":"Every record tagged colorectal cancer."}]},"sortKeys":{"year":0}},{"id":"florian-roser","name":"Florian Roser","tldr":"Neurosurgeon specialising in brain and skull base tumours, serving as Chief Medical Officer of Cleveland Clinic Abu Dhabi.","route":"/people/florian-roser/","kind":"person","round":true,"avatar":"person","sub":"Chief Medical Officer · Cleveland Clinic Abu Dhabi","facets":{"kind":["Person"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"neuro-oncology","href":"/tagged/neuro-oncology/","tip":"Every record tagged neuro-oncology."},{"label":"neurosurgery","href":"/tagged/neurosurgery/","tip":"Every record tagged neurosurgery."}]},"sortKeys":{"year":0}},{"id":"francisco-berrospi-espinoza","name":"Francisco Berrospi Espinoza","tldr":"Cancer surgeon who heads Peru's national cancer institute, INEN, after more than two decades as an abdominal surgeon there.","route":"/people/francisco-berrospi-espinoza/","kind":"person","round":true,"avatar":"person","sub":"Jefe Institucional (Institutional Head) of INEN · Instituto Nacional de Enfermedades Neoplásicas","facets":{"kind":["Person"],"cancers":["Gastric & gastro-oesophageal junction cancer","Hepatocellular carcinoma","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"surgical-oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical-oncology."}]},"sortKeys":{"year":0}},{"id":"franck-morschhauser","name":"Franck Morschhauser","tldr":"Lille haematologist and President of LYSA, the French-Belgian lymphoma cooperative group, who led the RELEVANCE trial of chemotherapy-free therapy in follicular lymphoma.","route":"/people/franck-morschhauser/","kind":"person","round":true,"avatar":"person","sub":"President · LYSA (The Lymphoma Study Association)","facets":{"kind":["Person"],"cancers":["Follicular lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"franco-cavalli","name":"Franco Cavalli","tldr":"Swiss oncologist who presides over the board of the international study group that runs clinical trials in lymphomas arising outside the lymph nodes.","route":"/people/franco-cavalli/","kind":"person","logo":"/portraits/franco-cavalli.jpg","round":true,"avatar":"person","sub":"President of the Board, International Extranodal Lymphoma Study Group · International Extranodal Lymphoma Study Group","facets":{"kind":["Person"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."},{"label":"clinical-trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical-trials."}]},"sortKeys":{"year":0}},{"id":"frederique-penault-llorca","name":"Frédérique Penault-Llorca","tldr":"Professor who directs Centre Jean Perrin, the comprehensive cancer centre for the Auvergne region in Clermont-Ferrand, now in her second five-year term.","route":"/people/frederique-penault-llorca/","kind":"person","logo":"/portraits/frederique-penault-llorca.jpg","round":true,"avatar":"person","sub":"Directrice Générale (Director General), Centre Jean Perrin · Centre Jean Perrin","facets":{"kind":["Person"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"geerard-beets","name":"Geerard Beets","tldr":"Colorectal surgeon and ESSO President, internationally known for watch-and-wait organ preservation in rectal cancer.","route":"/people/geerard-beets/","kind":"person","round":true,"avatar":"person","sub":"President · European Society of Surgical Oncology","facets":{"kind":["Person"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"colorectal cancer","href":"/tagged/colorectal-cancer/","tip":"Every record tagged colorectal cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"georges-pascal-haber","name":"Georges-Pascal Haber","tldr":"Urologic oncologist and robotic surgeon who is Chief Executive Officer of Cleveland Clinic Abu Dhabi.","route":"/people/georges-pascal-haber/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer · Cleveland Clinic Abu Dhabi","facets":{"kind":["Person"],"cancers":["Renal cell carcinoma","Prostate cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"urologic oncology","href":"/tagged/urologic-oncology/","tip":"Every record tagged urologic oncology."},{"label":"robotic surgery","href":"/tagged/robotic-surgery/","tip":"Every record tagged robotic surgery."}]},"sortKeys":{"year":0}},{"id":"gerardo-legaspi","name":"Gerardo D. Legaspi","tldr":"Physician who directs the Philippine General Hospital, the largest government tertiary hospital in the Philippines and the national referral centre run by the University of the Philippines Manila.","route":"/people/gerardo-legaspi/","kind":"person","round":true,"avatar":"person","sub":"Director of the Philippine General Hospital · Philippine General Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"public-hospital","href":"/tagged/public-hospital/","tip":"Every record tagged public-hospital."}]},"sortKeys":{"year":0}},{"id":"gilles-vassal","name":"Gilles Vassal","tldr":"Gustave Roussy paediatric oncologist and past SIOPE president who leads its oncopolicy work and helped shape European paediatric medicines regulation.","route":"/people/gilles-vassal/","kind":"person","round":true,"avatar":"person","sub":"Board member, Oncopolicy · SIOP Europe (European Society for Paediatric Oncology)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"paediatric oncology","href":"/tagged/paediatric-oncology/","tip":"Every record tagged paediatric oncology."},{"label":"regulation","href":"/tagged/regulation/","tip":"Every record tagged regulation."}]},"sortKeys":{"year":0}},{"id":"giovanni-blandino","name":"Giovanni Blandino","tldr":"Molecular oncologist known for mutant p53 research, appointed Scientific Director of Rome's Regina Elena National Cancer Institute in 2026.","route":"/people/giovanni-blandino/","kind":"person","round":true,"avatar":"person","sub":"Scientific Director, IRCCS Regina Elena National Cancer Institute · IRCCS Regina Elena National Cancer Institute","facets":{"kind":["Person"],"cancers":["Triple-negative breast cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"molecular oncology","href":"/tagged/molecular-oncology/","tip":"Every record tagged molecular oncology."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."}]},"sortKeys":{"year":0}},{"id":"goh-boon-cher","name":"Goh Boon Cher","tldr":"Senior medical oncologist and translational researcher who leads research at NCIS, with a long record in experimental therapeutics and head and neck cancer.","route":"/people/goh-boon-cher/","kind":"person","round":true,"avatar":"person","sub":"Deputy Director (Research) · National University Hospital / National University Cancer Institute, Singapore","facets":{"kind":["Person"],"cancers":["Head and neck squamous cell carcinoma","Nasopharyngeal carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."},{"label":"drug development","href":"/tagged/drug-development/","tip":"Every record tagged drug development."}]},"sortKeys":{"year":0}},{"id":"han-kwang-yang","name":"Han-Kwang Yang","tldr":"Leading Korean gastric cancer surgeon and KLASS trial investigator who is President of the National Cancer Center Korea.","route":"/people/han-kwang-yang/","kind":"person","round":true,"avatar":"person","sub":"President · National Cancer Center Korea","facets":{"kind":["Person"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gastric cancer","href":"/tagged/gastric-cancer/","tip":"Every record tagged gastric cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"hanno-glimm","name":"Hanno Glimm","tldr":"Medical oncologist who co-directs NCT/UCC Dresden and co-leads the NCT/DKFZ MASTER precision oncology programme for rare and young-onset cancers.","route":"/people/hanno-glimm/","kind":"person","round":true,"avatar":"person","sub":"Managing Director (Geschäftsführender Direktor); Head, Department of Translational Medical Oncology · NCT/UCC Dresden, University Hospital Carl Gustav Carus","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"precision oncology","href":"/tagged/precision-oncology/","tip":"Every record tagged precision oncology."},{"label":"cancer genomics","href":"/tagged/cancer-genomics/","tip":"Every record tagged cancer genomics."}]},"sortKeys":{"year":0}},{"id":"helen-mertens","name":"Helen Mertens","tldr":"Gynaecologist with a doctorate in gynaecological cancer research who chairs the executive board of Maastricht UMC+, the university medical centre that runs the Maastricht comprehensive cancer centre.","route":"/people/helen-mertens/","kind":"person","round":true,"avatar":"person","sub":"Voorzitter Raad van Bestuur (Chair of the Executive Board), Maastricht UMC+ · Maastricht UMC+ Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"hidetoshi-hayashi","name":"Hidetoshi Hayashi","tldr":"Vice-President of JSMO and thoracic medical oncologist at Kindai University known for clinical trials of targeted therapies in lung cancer.","route":"/people/hidetoshi-hayashi/","kind":"person","round":true,"avatar":"person","sub":"Vice-President · Japanese Society of Medical Oncology","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."}]},"sortKeys":{"year":0}},{"id":"hien-le","name":"Hien Le","tldr":"Adelaide radiation oncologist who chairs TROG's Scientific Committee and is its President Elect.","route":"/people/hien-le/","kind":"person","round":true,"avatar":"person","sub":"President Elect and Chair of the Scientific Committee · TROG Cancer Research","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."}]},"sortKeys":{"year":0}},{"id":"hitoshi-ishikawa","name":"Hitoshi Ishikawa","tldr":"Radiation specialist who has directed QST Hospital in Chiba, Japan's pioneering carbon ion radiotherapy hospital, since April 2024.","route":"/people/hitoshi-ishikawa/","kind":"person","round":true,"avatar":"person","sub":"Director of QST Hospital · QST Hospital (National Institutes for Quantum Science and Technology)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"particle-therapy","href":"/tagged/particle-therapy/","tip":"Every record tagged particle-therapy."}]},"sortKeys":{"year":0}},{"id":"hu-junbo","name":"Hu Junbo","tldr":"Gastrointestinal surgeon who has been President of Tongji Hospital in Wuhan, one of China's top-ranked general hospitals, since December 2023.","route":"/people/hu-junbo/","kind":"person","round":true,"avatar":"person","sub":"President (院长) and Deputy Party Secretary, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Tongji Hospital, Huazhong University of Science and Technology","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"hubert-serve","name":"Hubert Serve","tldr":"Leukaemia specialist heading haematology and oncology at University Hospital Frankfurt and co-author of the pivotal RATIFY midostaurin trial.","route":"/people/hubert-serve/","kind":"person","round":true,"avatar":"person","sub":"Director, Department of Internal Medicine 2 (Hematology/Oncology) · University Cancer Center Frankfurt (UCT)","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"ian-davis","name":"Ian Davis","tldr":"Melbourne medical oncologist who chairs ANZUP, the Australia and New Zealand urogenital and prostate cancer trials group.","route":"/people/ian-davis/","kind":"person","round":true,"avatar":"person","sub":"Chair · ANZUP Cancer Trials Group","facets":{"kind":["Person"],"cancers":["Prostate cancer","Renal cell carcinoma","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"prostate cancer","href":"/tagged/prostate-cancer/","tip":"Every record tagged prostate cancer."},{"label":"genitourinary oncology","href":"/tagged/genitourinary-oncology/","tip":"Every record tagged genitourinary oncology."}]},"sortKeys":{"year":0}},{"id":"igor-kiss","name":"Igor Kiss","tldr":"Medical oncologist responsible for clinical care at Masaryk Memorial Cancer Institute, with expertise in gastrointestinal oncology.","route":"/people/igor-kiss/","kind":"person","round":true,"avatar":"person","sub":"Director for Medical Care · Masaryk Memorial Cancer Institute","facets":{"kind":["Person"],"cancers":["Colorectal cancer","Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"colorectal cancer","href":"/tagged/colorectal-cancer/","tip":"Every record tagged colorectal cancer."},{"label":"medical oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical oncology."}]},"sortKeys":{"year":0}},{"id":"isabel-rubio","name":"Isabel T. Rubio","tldr":"Breast surgeon and ESSO Past-President who heads breast surgical oncology at Clínica Universidad de Navarra in Madrid.","route":"/people/isabel-rubio/","kind":"person","round":true,"avatar":"person","sub":"Past-President · European Society of Surgical Oncology","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"iwona-lugowska","name":"Iwona Ługowska","tldr":"Polish medical oncologist and sarcoma specialist who serves as President of the Organisation of European Cancer Institutes.","route":"/people/iwona-lugowska/","kind":"person","round":true,"avatar":"person","sub":"President · Organisation of European Cancer Institutes","facets":{"kind":["Person"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"sarcoma","href":"/tagged/sarcoma/","tip":"Every record tagged sarcoma."},{"label":"cancer centre accreditation","href":"/tagged/cancer-centre-accreditation/","tip":"Every record tagged cancer centre accreditation."}]},"sortKeys":{"year":0}},{"id":"j-silvio-gutkind","name":"J. Silvio Gutkind","tldr":"Cancer pharmacologist at UC San Diego known for work on G-protein signalling and mTOR-targeted therapy in head and neck cancer.","route":"/people/j-silvio-gutkind/","kind":"person","round":true,"avatar":"person","sub":"Associate Director, Basic Science; Professor and Chair, Department of Pharmacology · UC San Diego Moores Cancer Center","facets":{"kind":["Person"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."},{"label":"signalling","href":"/tagged/signalling/","tip":"Every record tagged signalling."}]},"sortKeys":{"year":0}},{"id":"jackson-orem","name":"Jackson Orem","tldr":"Medical oncologist who has led the Uganda Cancer Institute in Kampala, East Africa's principal cancer research and treatment centre.","route":"/people/jackson-orem/","kind":"person","round":true,"avatar":"person","sub":"Director · Uganda Cancer Institute","facets":{"kind":["Person"],"cancers":["Kaposi sarcoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Kaposi sarcoma","href":"/cancers/kaposi-sarcoma/","tip":"Kaposi sarcoma is a blood-vessel cancer caused by the herpesvirus HHV-8, made famous by the AIDS epidemic. In people with HIV, antiretroviral therapy alone often shrinks it; liposomal doxorubicin or paclitaxel treat advanced disease, and it remains among the commonest cancers in sub-Saharan Africa, where paclitaxel is often unaffordable."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"global oncology","href":"/tagged/global-oncology/","tip":"Every record tagged global oncology."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."}]},"sortKeys":{"year":0}},{"id":"jalid-sehouli","name":"Jalid Sehouli","tldr":"Berlin gynaecological oncologist and ESGO President, a leading ovarian cancer surgeon and trialist within the AGO study group.","route":"/people/jalid-sehouli/","kind":"person","logo":"/portraits/jalid-sehouli.jpg","round":true,"avatar":"person","sub":"President · European Society of Gynaecological Oncology","facets":{"kind":["Person"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gynaecological oncology","href":"/tagged/gynaecological-oncology/","tip":"Every record tagged gynaecological oncology."},{"label":"ovarian cancer","href":"/tagged/ovarian-cancer/","tip":"Every record tagged ovarian cancer."}]},"sortKeys":{"year":0}},{"id":"james-brenton","name":"James Brenton","tldr":"Cambridge medical oncologist and Interim Deputy Director of the CRUK Cambridge Institute, a leader in ovarian cancer genomics and ctDNA monitoring.","route":"/people/james-brenton/","kind":"person","round":true,"avatar":"person","sub":"Interim Deputy Director · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","facets":{"kind":["Person"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"ovarian cancer","href":"/tagged/ovarian-cancer/","tip":"Every record tagged ovarian cancer."},{"label":"cancer genomics","href":"/tagged/cancer-genomics/","tip":"Every record tagged cancer genomics."}]},"sortKeys":{"year":0}},{"id":"james-r-downing","name":"James R. Downing","tldr":"Hematopathologist and cancer genomics pioneer who has led St. Jude Children's Research Hospital since 2014.","route":"/people/james-r-downing/","kind":"person","round":true,"avatar":"person","sub":"President and Chief Executive Officer · St. Jude Children's Research Hospital","facets":{"kind":["Person"],"cancers":["Acute lymphoblastic leukaemia","Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"paediatric oncology","href":"/tagged/paediatric-oncology/","tip":"Every record tagged paediatric oncology."},{"label":"leukemia","href":"/tagged/leukemia/","tip":"Every record tagged leukemia."}]},"sortKeys":{"year":0}},{"id":"janja-ocvirk","name":"Janja Ocvirk","tldr":"Medical oncologist and Medical Director of the Institute of Oncology Ljubljana, with research in melanoma and colorectal cancer.","route":"/people/janja-ocvirk/","kind":"person","logo":"/portraits/janja-ocvirk.png","round":true,"avatar":"person","sub":"Medical Director (Strokovna direktorica) · Institute of Oncology Ljubljana","facets":{"kind":["Person"],"cancers":["Melanoma","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"melanoma","href":"/tagged/melanoma/","tip":"Every record tagged melanoma."},{"label":"colorectal cancer","href":"/tagged/colorectal-cancer/","tip":"Every record tagged colorectal cancer."}]},"sortKeys":{"year":0}},{"id":"jason-carroll","name":"Jason Carroll","tldr":"Molecular oncologist and Interim Director of the Cancer Research UK Cambridge Institute, known for mapping how the oestrogen receptor drives breast cancer.","route":"/people/jason-carroll/","kind":"person","round":true,"avatar":"person","sub":"Interim Director · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"basic science","href":"/tagged/basic-science/","tip":"Every record tagged basic science."}]},"sortKeys":{"year":0}},{"id":"jean-pierre-delord","name":"Jean-Pierre Delord","tldr":"Medical oncologist who leads the IUCT Oncopole cooperation group in Toulouse and runs early-phase cancer drug trials.","route":"/people/jean-pierre-delord/","kind":"person","round":true,"avatar":"person","sub":"Administrator of the GCS (Groupement de Coopération Sanitaire) · IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","facets":{"kind":["Person"],"cancers":["Endometrial cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"early-phase trials","href":"/tagged/early-phase-trials/","tip":"Every record tagged early-phase trials."},{"label":"medical oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical oncology."}]},"sortKeys":{"year":0}},{"id":"jeffrey-miller","name":"Jeffrey Miller","tldr":"Physician who directs the Masonic Cancer Center at the University of Minnesota, the NCI-designated comprehensive cancer centre in Minneapolis.","route":"/people/jeffrey-miller/","kind":"person","round":true,"avatar":"person","sub":"Director, Masonic Cancer Center, University of Minnesota · Masonic Cancer Center, University of Minnesota","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"jens-overgaard","name":"Jens Overgaard","tldr":"Pioneering radiation oncologist at Aarhus who led the DAHANCA trials on hypoxia modification and radiotherapy for head and neck cancer.","route":"/people/jens-overgaard/","kind":"person","round":true,"avatar":"person","sub":"Professor, Department of Clinical Medicine - The Department of Oncology · Aarhus University Hospital","facets":{"kind":["Person"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."}]},"sortKeys":{"year":0}},{"id":"jesse-otegbayo","name":"Jesse Abiodun Otegbayo","tldr":"Professor of medicine and gastroenterologist who is Chief Medical Director of University College Hospital, Ibadan, Nigeria's oldest teaching hospital.","route":"/people/jesse-otegbayo/","kind":"person","round":true,"avatar":"person","sub":"Chief Medical Director, University College Hospital, Ibadan · University College Hospital, Ibadan","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"jesus-san-miguel","name":"Jesús San Miguel","tldr":"Hematologist who chairs the Cancer Center CUN internal scientific committee and is one of the most influential clinical investigators in multiple myeloma.","route":"/people/jesus-san-miguel/","kind":"person","logo":"/portraits/jesus-san-miguel.jpg","round":true,"avatar":"person","sub":"President, Internal Scientific Committee · Cancer Center Clínica Universidad de Navarra / CIMA","facets":{"kind":["Person"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"multiple myeloma","href":"/tagged/multiple-myeloma/","tip":"Every record tagged multiple myeloma."},{"label":"hematology","href":"/tagged/hematology/","tip":"Every record tagged hematology."}]},"sortKeys":{"year":0}},{"id":"fan-jia","name":"Jia Fan","tldr":"Jia Fan leads one of the world's busiest liver cancer surgery and transplant programmes and the proteogenomic studies that mapped how hepatitis B-related liver cancer differs at the molecular level.","route":"/people/fan-jia/","kind":"person","round":true,"avatar":"person","sub":"President, Zhongshan Hospital, Fudan University; Liver Cancer Institute · Zhongshan Hospital, Fudan University","facets":{"kind":["Person"],"cancers":["Hepatocellular carcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."},{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"liver cancer","href":"/tagged/liver-cancer/","tip":"Every record tagged liver cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"jihui-hao","name":"Jihui Hao","tldr":"Physician-scientist who is President of Tianjin Medical University Cancer Institute and Hospital, one of China's largest specialist cancer hospitals and a National Clinical Research Center for Malignant Tumors.","route":"/people/jihui-hao/","kind":"person","round":true,"avatar":"person","sub":"President, Tianjin Medical University Cancer Institute and Hospital · Tianjin Medical University Cancer Institute and Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"jim-woodgett","name":"Jim Woodgett","tldr":"Cell signalling scientist who has been President and Scientific Director of the Terry Fox Research Institute, the research arm of The Terry Fox Foundation, since 2021.","route":"/people/jim-woodgett/","kind":"person","logo":"/portraits/jim-woodgett.jpg","round":true,"avatar":"person","sub":"President and Scientific Director, Terry Fox Research Institute · Terry Fox Research Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."},{"label":"philanthropy","href":"/tagged/philanthropy/","tip":"Every record tagged philanthropy."}]},"sortKeys":{"year":0}},{"id":"jimmy-so","name":"Jimmy So","tldr":"Gastric cancer surgeon who heads surgical oncology at NCIS and coordinates its multidisciplinary tumour groups.","route":"/people/jimmy-so/","kind":"person","round":true,"avatar":"person","sub":"Head, Division of Surgical Oncology; Associate Director (Tumour Groups) · National University Hospital / National University Cancer Institute, Singapore","facets":{"kind":["Person"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gastric cancer","href":"/tagged/gastric-cancer/","tip":"Every record tagged gastric cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"jin-seok-ahn","name":"Jin Seok Ahn","tldr":"Medical oncologist serving as 14th President of the Korean Cancer Study Group, Korea's main academic cooperative trials group.","route":"/people/jin-seok-ahn/","kind":"person","round":true,"avatar":"person","sub":"President (14th) · Korean Cancer Study Group","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"joann-sweasy","name":"Joann B. Sweasy","tldr":"DNA repair scientist who directs the Fred & Pamela Buffett Cancer Center in Omaha and the UNMC Eppley Institute.","route":"/people/joann-sweasy/","kind":"person","round":true,"avatar":"person","sub":"Director, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center · Fred & Pamela Buffett Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"joaquin-martinez-lopez","name":"Joaquín Martínez-López","tldr":"Haematologist who heads the Haematology Department at Hospital 12 de Octubre and the joint H12O-CNIO haematological malignancies unit, known for myeloma and MRD research.","route":"/people/joaquin-martinez-lopez/","kind":"person","round":true,"avatar":"person","sub":"Head of the Haematology Department · Hospital Universitario 12 de Octubre","facets":{"kind":["Person"],"cancers":["Multiple myeloma","Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"multiple myeloma","href":"/tagged/multiple-myeloma/","tip":"Every record tagged multiple myeloma."}]},"sortKeys":{"year":0}},{"id":"johanna-joyce","name":"Johanna Joyce","tldr":"Tumour immunologist at Ludwig Lausanne who began a two-year term as President of the European Association for Cancer Research in June 2026.","route":"/people/johanna-joyce/","kind":"person","logo":"/portraits/johanna-joyce.jpg","round":true,"avatar":"person","sub":"President of the European Association for Cancer Research (2026-2028) · European Association for Cancer Research","facets":{"kind":["Person"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunology","href":"/tagged/immunology/","tip":"Every record tagged immunology."},{"label":"society","href":"/tagged/society/","tip":"Every record tagged society."}]},"sortKeys":{"year":0}},{"id":"johanna-mattson","name":"Johanna Mattson","tldr":"Oncologist who directs the HUS Comprehensive Cancer Center in Helsinki, Finland's largest cancer treatment centre.","route":"/people/johanna-mattson/","kind":"person","round":true,"avatar":"person","sub":"Senior Medical Director and Director of Division, HUS Comprehensive Cancer Center · HUS Comprehensive Cancer Center, Helsinki University Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"john-kennedy","name":"John Kennedy","tldr":"Professor who is Medical Director of Trinity St James's Cancer Institute, Ireland's first academic comprehensive cancer institute, in Dublin.","route":"/people/john-kennedy/","kind":"person","round":true,"avatar":"person","sub":"Medical Director, Trinity St James's Cancer Institute · Trinity St James's Cancer Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"john-stagg","name":"John Stagg","tldr":"Immunologist who studies why tumours resist immunotherapy and directs the Goodman Cancer Institute, McGill University's cancer research institute in Montreal.","route":"/people/john-stagg/","kind":"person","round":true,"avatar":"person","sub":"Director of the Rosalind and Morris Goodman Cancer Institute · Rosalind and Morris Goodman Cancer Institute, McGill University","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"jon-irish","name":"Jon Irish","tldr":"Head and neck surgical oncologist who leads the cancer programmes of Ontario Health, the agency that absorbed Cancer Care Ontario, and chairs its Clinical Council.","route":"/people/jon-irish/","kind":"person","round":true,"avatar":"person","sub":"Vice President, Clinical, Cancer Programs, Ontario Health · Ontario Health (Cancer Care Ontario)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"government","href":"/tagged/government/","tip":"Every record tagged government."}]},"sortKeys":{"year":0}},{"id":"jonathan-benger","name":"Jonathan Benger","tldr":"Emergency physician who became Chief Executive of NICE, the body that appraises new cancer medicines and issues clinical guidance for the NHS, in December 2025.","route":"/people/jonathan-benger/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive of NICE (since December 2025) · National Institute for Health and Care Excellence","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hta","href":"/tagged/hta/","tip":"Every record tagged hta."},{"label":"policy","href":"/tagged/policy/","tip":"Every record tagged policy."}]},"sortKeys":{"year":0}},{"id":"josep-llovet","name":"Josep M. Llovet","tldr":"Led SHARP, which made sorafenib the first systemic therapy for liver cancer, and created the BCLC staging system.","route":"/people/josep-llovet/","kind":"person","round":true,"avatar":"person","sub":"Director, Liver Cancer Program, Icahn School of Medicine at Mount Sinai; Professor, University of Barcelona · The Mount Sinai Hospital / Tisch Cancer Institute","facets":{"kind":["Person"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[{"label":"hcc","href":"/tagged/hcc/","tip":"Every record tagged hcc."},{"label":"staging","href":"/tagged/staging/","tip":"Every record tagged staging."},{"label":"trialist","href":"/tagged/trialist/","tip":"Every record tagged trialist."},{"label":"liver cancer","href":"/tagged/liver-cancer/","tip":"Every record tagged liver cancer."},{"label":"hepatocellular carcinoma","href":"/tagged/hepatocellular-carcinoma/","tip":"Every record tagged hepatocellular carcinoma."}]},"sortKeys":{"year":0}},{"id":"joseph-gligorov","name":"Joseph Gligorov","tldr":"Medical oncologist at Hôpital Tenon who is executive director of the Institut Universitaire de Cancérologie AP-HP Sorbonne Université, the OECI-accredited university cancer institute in Paris.","route":"/people/joseph-gligorov/","kind":"person","round":true,"avatar":"person","sub":"Directeur Exécutif (Executive Director), Institut Universitaire de Cancérologie AP-HP Sorbonne Université · Institut Universitaire de Cancérologie AP-HP Sorbonne Université","facets":{"kind":["Person"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"joseph-ross","name":"Joseph S. Ross","tldr":"Yale health policy researcher on the YODA Project leadership team, known for work on FDA regulation and trial transparency.","route":"/people/joseph-ross/","kind":"person","round":true,"avatar":"person","sub":"Professor of Medicine (General Medicine) and of Public Health (Health Policy) · Yale University Open Data Access (YODA) Project","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"regulation","href":"/tagged/regulation/","tip":"Every record tagged regulation."},{"label":"data sharing","href":"/tagged/data-sharing/","tip":"Every record tagged data sharing."}]},"sortKeys":{"year":0}},{"id":"julian-redhead","name":"Julian Redhead","tldr":"Emergency medicine consultant who became Trust Chief Executive of Imperial College Healthcare NHS Trust in April 2026 after serving as its medical director.","route":"/people/julian-redhead/","kind":"person","round":true,"avatar":"person","sub":"Trust Chief Executive, Imperial College Healthcare NHS Trust · Imperial College Healthcare NHS Trust / Imperial College London Cancer Research","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"julio-oliveira","name":"Júlio Oliveira","tldr":"Medical oncologist who chairs the board of IPO Porto, the public cancer hospital serving northern Portugal, since 2022.","route":"/people/julio-oliveira/","kind":"person","round":true,"avatar":"person","sub":"Presidente do Conselho de Administração (Chair of the Board of Directors) of IPO Porto · Instituto Português de Oncologia do Porto Francisco Gentil","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"medical-oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical-oncology."}]},"sortKeys":{"year":0}},{"id":"julio-saez-rodriguez","name":"Julio Saez-Rodriguez","tldr":"Systems biologist heading research at EMBL-EBI, known for computational methods to model signalling networks and predict cancer drug response.","route":"/people/julio-saez-rodriguez/","kind":"person","round":true,"avatar":"person","sub":"Head of Research · EMBL's European Bioinformatics Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"computational biology","href":"/tagged/computational-biology/","tip":"Every record tagged computational biology."},{"label":"drug response","href":"/tagged/drug-response/","tip":"Every record tagged drug response."}]},"sortKeys":{"year":0}},{"id":"jurgen-kuball","name":"Jürgen Kuball","tldr":"Utrecht haematologist and immunotherapy researcher on the daily board of UMC Utrecht's cancer programme, known for gamma-delta T cell receptor-engineered cell therapies.","route":"/people/jurgen-kuball/","kind":"person","round":true,"avatar":"person","sub":"Daily Board member, Strategic Program Cancer · UMC Utrecht Cancer Center","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"jurgen-weitz","name":"Jürgen Weitz","tldr":"Surgical oncologist who co-directs NCT/UCC Dresden and leads gastrointestinal cancer surgery at University Hospital Carl Gustav Carus.","route":"/people/jurgen-weitz/","kind":"person","round":true,"avatar":"person","sub":"Managing Director (Geschäftsführender Direktor); Director, Department of Visceral, Thoracic and Vascular Surgery · NCT/UCC Dresden, University Hospital Carl Gustav Carus","facets":{"kind":["Person"],"cancers":["Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."},{"label":"gastrointestinal cancer","href":"/tagged/gastrointestinal-cancer/","tip":"Every record tagged gastrointestinal cancer."}]},"sortKeys":{"year":0}},{"id":"kadir-mutlu-hayran","name":"Kadir Mutlu Hayran","tldr":"Professor who directs the Hacettepe University Cancer Institute in Ankara, one of Turkey's leading academic cancer research and treatment institutes.","route":"/people/kadir-mutlu-hayran/","kind":"person","round":true,"avatar":"person","sub":"Director of the Hacettepe University Cancer Institute · Hacettepe University Cancer Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"academic-oncology","href":"/tagged/academic-oncology/","tip":"Every record tagged academic-oncology."}]},"sortKeys":{"year":0}},{"id":"karen-lu","name":"Karen H. Lu","tldr":"Gynecologic oncologist known for research on hereditary and early-detection strategies in gynecologic cancers; SGO Immediate Past President.","route":"/people/karen-lu/","kind":"person","round":true,"avatar":"person","sub":"Immediate Past President · Society of Gynecologic Oncology","facets":{"kind":["Person"],"cancers":["Ovarian cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gynecologic oncology","href":"/tagged/gynecologic-oncology/","tip":"Every record tagged gynecologic oncology."},{"label":"cancer prevention","href":"/tagged/cancer-prevention/","tip":"Every record tagged cancer prevention."}]},"sortKeys":{"year":0}},{"id":"karen-kelly","name":"Karen Kelly","tldr":"Thoracic medical oncologist who serves as CEO of the International Association for the Study of Lung Cancer.","route":"/people/karen-kelly/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer · International Association for the Study of Lung Cancer","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer","Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."}]},"sortKeys":{"year":0}},{"id":"karim-vermaelen","name":"Karim Vermaelen","tldr":"Thoracic oncologist and tumour immunologist who chairs the Cancer Research Institute Ghent at Ghent University / UZ Gent.","route":"/people/karim-vermaelen/","kind":"person","round":true,"avatar":"person","sub":"Chairperson, CRIG Steering Committee (2026-2028) · Ghent University Hospital / Cancer Research Institute Ghent","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"karolina-palucka","name":"Karolina Palucka","tldr":"Immunologist who directs the NCI-designated JAX Cancer Center at The Jackson Laboratory and holds its Edison T. Liu Endowed Chair in Cancer Research.","route":"/people/karolina-palucka/","kind":"person","round":true,"avatar":"person","sub":"Director, JAX Cancer Center, The Jackson Laboratory · The Jackson Laboratory Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"katsuhiko-uesaka","name":"Katsuhiko Uesaka","tldr":"Physician who has led Shizuoka Cancer Center, one of Japan's three largest cancer centres by patient volume, since April 2023.","route":"/people/katsuhiko-uesaka/","kind":"person","round":true,"avatar":"person","sub":"President of Shizuoka Cancer Center · Shizuoka Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer-centre","href":"/tagged/cancer-centre/","tip":"Every record tagged cancer-centre."}]},"sortKeys":{"year":0}},{"id":"ken-smith","name":"Ken Smith","tldr":"Clinician-scientist and immunologist who directs WEHI, Australia's oldest medical research institute and a major centre for cancer biology.","route":"/people/ken-smith/","kind":"person","round":true,"avatar":"person","sub":"Director · Walter and Eliza Hall Institute of Medical Research","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunology","href":"/tagged/immunology/","tip":"Every record tagged immunology."}]},"sortKeys":{"year":0}},{"id":"kenneth-tanabe","name":"Kenneth K. Tanabe","tldr":"Massachusetts General Hospital surgical oncologist and 2026-2027 President of the Society of Surgical Oncology, with expertise in liver cancer and melanoma.","route":"/people/kenneth-tanabe/","kind":"person","round":true,"avatar":"person","sub":"President · Society of Surgical Oncology","facets":{"kind":["Person"],"cancers":["Hepatocellular carcinoma","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."},{"label":"liver cancer","href":"/tagged/liver-cancer/","tip":"Every record tagged liver cancer."}]},"sortKeys":{"year":0}},{"id":"kent-stobart","name":"Kent Stobart","tldr":"Paediatric oncologist and certified physician executive who has led CancerCare Manitoba, the provincial cancer agency, as President and CEO since November 2025.","route":"/people/kent-stobart/","kind":"person","round":true,"avatar":"person","sub":"President and Chief Executive Officer, CancerCare Manitoba · CancerCare Manitoba","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"kjetil-tasken","name":"Kjetil Taskén","tldr":"Immunologist and head of the Institute for Cancer Research at Oslo University Hospital's Norwegian Radium Hospital, leading Norway's largest cancer research institute.","route":"/people/kjetil-tasken/","kind":"person","round":true,"avatar":"person","sub":"Head of the Institute for Cancer Research · Oslo University Hospital, The Norwegian Radium Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunology","href":"/tagged/immunology/","tip":"Every record tagged immunology."},{"label":"precision oncology","href":"/tagged/precision-oncology/","tip":"Every record tagged precision oncology."}]},"sortKeys":{"year":0}},{"id":"koichi-fukunaga","name":"Koichi Fukunaga","tldr":"Respiratory physician who heads Keio University Hospital in Tokyo, a leading Japanese academic hospital with designated cancer centre status.","route":"/people/koichi-fukunaga/","kind":"person","round":true,"avatar":"person","sub":"Director General · Keio University Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"respiratory medicine","href":"/tagged/respiratory-medicine/","tip":"Every record tagged respiratory medicine."}]},"sortKeys":{"year":0}},{"id":"konstanze-doehner","name":"Konstanze Döhner","tldr":"Ulm haematologist and President of the European Hematology Association, a leading figure in the molecular genetics and risk classification of acute myeloid leukaemia.","route":"/people/konstanze-doehner/","kind":"person","round":true,"avatar":"person","sub":"President · European Hematology Association","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."}]},"sortKeys":{"year":0}},{"id":"kunle-odunsi","name":"Kunle Odunsi","tldr":"Gynaecologic oncologist and immunotherapy researcher who directs the University of Chicago Medicine Comprehensive Cancer Center.","route":"/people/kunle-odunsi/","kind":"person","round":true,"avatar":"person","sub":"Director · University of Chicago Medicine Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."},{"label":"ovarian cancer","href":"/tagged/ovarian-cancer/","tip":"Every record tagged ovarian cancer."}]},"sortKeys":{"year":0}},{"id":"ls-shashidhara","name":"L. S. Shashidhara","tldr":"Geneticist and developmental biologist who directs the National Centre for Biological Sciences in Bengaluru, a research unit of the Tata Institute of Fundamental Research.","route":"/people/ls-shashidhara/","kind":"person","logo":"/portraits/ls-shashidhara.jpg","round":true,"avatar":"person","sub":"Centre Director, National Centre for Biological Sciences (NCBS), Bengaluru · National Centre for Biological Sciences","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"lars-zender","name":"Lars Zender","tldr":"Medical oncologist and cancer biologist at Tübingen, known for work on senescence surveillance and functional genomics in liver cancer.","route":"/people/lars-zender/","kind":"person","logo":"/portraits/lars-zender.jpg","round":true,"avatar":"person","sub":"Deputy Speaker; Medical Director, Internal Medicine VIII (Medical Oncology and Pulmonology) · Comprehensive Cancer Center Tübingen-Stuttgart","facets":{"kind":["Person"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"liver cancer","href":"/tagged/liver-cancer/","tip":"Every record tagged liver cancer."},{"label":"cancer biology","href":"/tagged/cancer-biology/","tip":"Every record tagged cancer biology."}]},"sortKeys":{"year":0}},{"id":"le-van-quang","name":"Lê Văn Quảng","tldr":"Surgical oncologist who has directed Vietnam National Cancer Hospital (K Hospital) in Hanoi since 2020.","route":"/people/le-van-quang/","kind":"person","round":true,"avatar":"person","sub":"Director · Vietnam National Cancer Hospital (K Hospital)","facets":{"kind":["Person"],"cancers":["Head and neck squamous cell carcinoma","Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."},{"label":"global oncology","href":"/tagged/global-oncology/","tip":"Every record tagged global oncology."},{"label":"oeci-representative","href":"/tagged/oeci-representative/","tip":"Every record tagged oeci-representative."}]},"sortKeys":{"year":0}},{"id":"lei-zheng","name":"Lei Zheng","tldr":"Physician-scientist who is Executive Director of the Mays Cancer Center at UT Health San Antonio, the only NCI-designated cancer centre in South Texas.","route":"/people/lei-zheng/","kind":"person","round":true,"avatar":"person","sub":"Executive Director, Mays Cancer Center, and Vice President for Oncology, UT Health San Antonio · Mays Cancer Center at UT Health San Antonio","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"lim-soon-thye","name":"Lim Soon Thye","tldr":"Lymphoma specialist and Chief Executive Officer of the National Cancer Centre Singapore, the country's largest public cancer centre.","route":"/people/lim-soon-thye/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer · National Cancer Centre Singapore","facets":{"kind":["Person"],"cancers":["Peripheral T-cell lymphomas","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."}]},"sortKeys":{"year":0}},{"id":"lin-tongyu","name":"Lin Tongyu","tldr":"Physician who is President of Sichuan Cancer Hospital, the provincial specialist cancer hospital and institute in Chengdu with campuses in Wuhou and Tianfu.","route":"/people/lin-tongyu/","kind":"person","round":true,"avatar":"person","sub":"President (院长), Sichuan Cancer Hospital · Sichuan Cancer Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"louis-chesler","name":"Louis Chesler","tldr":"Paediatric oncologist and neuroblastoma researcher who leads Children's Cancer Institute in Sydney, Australia's dedicated childhood cancer research institute.","route":"/people/louis-chesler/","kind":"person","round":true,"avatar":"person","sub":"Executive Director, Children's Cancer Institute · Sydney Children's Hospitals Network / Children's Cancer Institute","facets":{"kind":["Person"],"cancers":["Neuroblastoma","Medulloblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."},{"label":"Medulloblastoma","href":"/cancers/medulloblastoma/","tip":"Medulloblastoma is the most common malignant childhood brain tumour, arising in the cerebellum. Surgery, radiation to the whole brain and spine, and chemotherapy cure about 70%, at a heavy cost to thinking and growth; treatment is now being tailored to four molecular subgroups so that the low-risk children get less."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"paediatric oncology","href":"/tagged/paediatric-oncology/","tip":"Every record tagged paediatric oncology."},{"label":"neuroblastoma","href":"/tagged/neuroblastoma/","tip":"Every record tagged neuroblastoma."}]},"sortKeys":{"year":0}},{"id":"luis-eduardo-martin-rodriguez","name":"Luis Eduardo Martín Rodríguez","tldr":"Physician who directs Cuba's Instituto Nacional de Oncología y Radiobiología in Havana, the country's lead institution for cancer treatment, research and training.","route":"/people/luis-eduardo-martin-rodriguez/","kind":"person","round":true,"avatar":"person","sub":"Director, Instituto Nacional de Oncología y Radiobiología (INOR), Havana · Instituto Nacional de Oncología y Radiobiología (INOR)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"luis-paz-ares","name":"Luis Paz-Ares","tldr":"Madrid medical oncologist who heads the joint 12 de Octubre-CNIO lung cancer clinical research unit and led the KEYNOTE-407 trial in squamous lung cancer.","route":"/people/luis-paz-ares/","kind":"person","round":true,"avatar":"person","sub":"Head of the H12O-CNIO Lung Cancer Clinical Research Unit · Hospital Universitario 12 de Octubre","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"mafalda-oliveira","name":"Mafalda Oliveira","tldr":"Barcelona breast oncologist who leads SOLTI, the Spanish academic breast cancer research group, and co-authors pivotal endocrine therapy trials.","route":"/people/mafalda-oliveira/","kind":"person","round":true,"avatar":"person","sub":"President (Presidenta) · SOLTI Cancer Research Group","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"magdolna-dank","name":"Magdolna Dank","tldr":"Hungarian oncologist who is Director-General of the National Institute of Oncology in Budapest, Hungary's national cancer centre.","route":"/people/magdolna-dank/","kind":"person","round":true,"avatar":"person","sub":"Director-General and Chief Physician, National Institute of Oncology, Budapest · National Institute of Oncology, Hungary","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"medical-oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical-oncology."}]},"sortKeys":{"year":0}},{"id":"marc-raaijmakers","name":"Marc H.G.P. Raaijmakers","tldr":"Erasmus MC haematologist and HOVON Vice Chair known for research on the bone marrow microenvironment in MDS.","route":"/people/marc-raaijmakers/","kind":"person","round":true,"avatar":"person","sub":"Vice Chair · HOVON","facets":{"kind":["Person"],"cancers":["Myelodysplastic syndromes / neoplasms","Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"MDS","href":"/tagged/mds/","tip":"Every record tagged MDS."}]},"sortKeys":{"year":0}},{"id":"marc-ychou","name":"Marc Ychou","tldr":"Medical oncologist who is Director General of the Institut du Cancer de Montpellier, the reference cancer centre for eastern Occitanie founded in 1923.","route":"/people/marc-ychou/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général (Director General), Institut du Cancer de Montpellier · Institut du Cancer de Montpellier (ICM)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"marco-herold","name":"Marco Herold","tldr":"Cancer biologist who leads the Olivia Newton-John Cancer Research Institute, the research arm of the Olivia Newton-John Cancer Wellness and Research Centre in Melbourne.","route":"/people/marco-herold/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer, Olivia Newton-John Cancer Research Institute · Olivia Newton-John Cancer Wellness and Research Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."},{"label":"genome-editing","href":"/tagged/genome-editing/","tip":"Every record tagged genome-editing."}]},"sortKeys":{"year":0}},{"id":"marco-vignetti","name":"Marco Vignetti","tldr":"Haematologist who presides over GIMEMA, Italy's adult haematological malignancies cooperative group, and co-authored its chemotherapy-free Ph+ ALL trial.","route":"/people/marco-vignetti/","kind":"person","round":true,"avatar":"person","sub":"President · GIMEMA","facets":{"kind":["Person"],"cancers":["Acute lymphoblastic leukaemia","Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"marek-svoboda","name":"Marek Svoboda","tldr":"Medical oncologist who leads the Masaryk Memorial Cancer Institute in Brno, the Czech Republic's largest dedicated cancer centre.","route":"/people/marek-svoboda/","kind":"person","logo":"/portraits/marek-svoboda.jpg","round":true,"avatar":"person","sub":"General Director · Masaryk Memorial Cancer Institute","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"medical oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical oncology."}]},"sortKeys":{"year":0}},{"id":"mario-campone","name":"Mario Campone","tldr":"Medical oncologist who is Director General of the Institut de Cancérologie de l'Ouest, the regional cancer centre for western France with sites in Angers and Nantes.","route":"/people/mario-campone/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général (Director General), Institut de Cancérologie de l'Ouest · Institut de Cancérologie de l'Ouest (ICO)","facets":{"kind":["Person"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"mark-burkard","name":"Mark E. Burkard","tldr":"Breast cancer physician scientist who has directed the Holden Comprehensive Cancer Center at the University of Iowa since October 2024.","route":"/people/mark-burkard/","kind":"person","round":true,"avatar":"person","sub":"Director, Holden Comprehensive Cancer Center, University of Iowa · Holden Comprehensive Cancer Center, University of Iowa","facets":{"kind":["Person"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"mark-middleton","name":"Mark Middleton","tldr":"Medical oncologist who co-directs Oxford Cancer, the city-wide partnership between the University of Oxford and Oxford University Hospitals.","route":"/people/mark-middleton/","kind":"person","round":true,"avatar":"person","sub":"Director, Oxford Cancer (co-director with Tim Elliott and Adam Mead) · Oxford Cancer (Oxford University Hospitals and University of Oxford)","facets":{"kind":["Person"],"cancers":["Melanoma","Gastric & gastro-oesophageal junction cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"medical-oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical-oncology."},{"label":"early-phase-trials","href":"/tagged/early-phase-trials/","tip":"Every record tagged early-phase-trials."}]},"sortKeys":{"year":0}},{"id":"martin-bornhauser","name":"Martin Bornhäuser","tldr":"Dresden haematologist and transplant physician who co-directs the NCT/UCC Dresden cancer centre and leads AML transplant trials.","route":"/people/martin-bornhauser/","kind":"person","round":true,"avatar":"person","sub":"Managing Director (Geschäftsführender Direktor); Director, Medizinische Klinik und Poliklinik I · NCT/UCC Dresden, University Hospital Carl Gustav Carus","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."}]},"sortKeys":{"year":0}},{"id":"martin-schuler","name":"Martin Schuler","tldr":"Medical oncologist and lung cancer trialist who is Deputy Director of the West German Cancer Center in Essen.","route":"/people/martin-schuler/","kind":"person","round":true,"avatar":"person","sub":"Deputy Director WTZ Essen · West German Cancer Center (WTZ), University Hospital Essen","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."}]},"sortKeys":{"year":0}},{"id":"matthew-powell","name":"Matthew A. Powell","tldr":"Gynecologic oncologist and endometrial cancer trialist who is President of the Society of Gynecologic Oncology.","route":"/people/matthew-powell/","kind":"person","round":true,"avatar":"person","sub":"President · Society of Gynecologic Oncology","facets":{"kind":["Person"],"cancers":["Endometrial cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gynecologic oncology","href":"/tagged/gynecologic-oncology/","tip":"Every record tagged gynecologic oncology."},{"label":"endometrial cancer","href":"/tagged/endometrial-cancer/","tip":"Every record tagged endometrial cancer."}]},"sortKeys":{"year":0}},{"id":"matthew-hurles","name":"Matthew Hurles","tldr":"Human geneticist who directs the Wellcome Sanger Institute, a world centre for cancer genome research.","route":"/people/matthew-hurles/","kind":"person","round":true,"avatar":"person","sub":"Director of the Wellcome Sanger Institute and Senior Group Leader · Wellcome Sanger Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"genomics","href":"/tagged/genomics/","tip":"Every record tagged genomics."}]},"sortKeys":{"year":0}},{"id":"matthew-vander-heiden","name":"Matthew Vander Heiden","tldr":"Physician-scientist and cancer metabolism expert who directs MIT's Koch Institute for Integrative Cancer Research.","route":"/people/matthew-vander-heiden/","kind":"person","round":true,"avatar":"person","sub":"Director · David H. Koch Institute for Integrative Cancer Research at MIT","facets":{"kind":["Person"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer metabolism","href":"/tagged/cancer-metabolism/","tip":"Every record tagged cancer metabolism."}]},"sortKeys":{"year":0}},{"id":"matthias-guckenberger","name":"Matthias Guckenberger","tldr":"Zurich radiation oncologist and ESTRO Past-President, a leading voice on stereotactic radiotherapy for oligometastases.","route":"/people/matthias-guckenberger/","kind":"person","round":true,"avatar":"person","sub":"Past-President · European Society for Radiotherapy and Oncology","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."}]},"sortKeys":{"year":0}},{"id":"maximilian-niyazi","name":"Maximilian Niyazi","tldr":"Radiation oncologist who speaks for the Comprehensive Cancer Center Tübingen-Stuttgart and directs radiation oncology at Tübingen University Hospital.","route":"/people/maximilian-niyazi/","kind":"person","round":true,"avatar":"person","sub":"Speaker (Sprecher) of the CCC Tübingen-Stuttgart · Comprehensive Cancer Center Tübingen-Stuttgart","facets":{"kind":["Person"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"neuro-oncology","href":"/tagged/neuro-oncology/","tip":"Every record tagged neuro-oncology."}]},"sortKeys":{"year":0}},{"id":"meredith-irwin","name":"Meredith Irwin","tldr":"Paediatric oncologist and neuroblastoma researcher who serves as Paediatrician-in-Chief at SickKids in Toronto.","route":"/people/meredith-irwin/","kind":"person","round":true,"avatar":"person","sub":"Paediatrician-in-Chief · The Hospital for Sick Children (SickKids)","facets":{"kind":["Person"],"cancers":["Neuroblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"paediatric oncology","href":"/tagged/paediatric-oncology/","tip":"Every record tagged paediatric oncology."},{"label":"neuroblastoma","href":"/tagged/neuroblastoma/","tip":"Every record tagged neuroblastoma."}]},"sortKeys":{"year":0}},{"id":"michael-boyer","name":"Michael Boyer","tldr":"Thoracic medical oncologist who has been chief executive of Chris O'Brien Lifehouse, Sydney's not-for-profit cancer hospital, since 2023.","route":"/people/michael-boyer/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer of Chris O'Brien Lifehouse · Chris O'Brien Lifehouse","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer","Head and neck squamous cell carcinoma","Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"thoracic-oncology","href":"/tagged/thoracic-oncology/","tip":"Every record tagged thoracic-oncology."}]},"sortKeys":{"year":0}},{"id":"michael-gnant","name":"Michael Gnant","tldr":"Viennese surgical oncologist who presides over the ABCSG and has led landmark adjuvant breast cancer trials such as ABCSG-12, ABCSG-18 and PALLAS.","route":"/people/michael-gnant/","kind":"person","logo":"/portraits/michael-gnant.png","round":true,"avatar":"person","sub":"President · Austrian Breast & Colorectal Cancer Study Group","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"michael-kerin","name":"Michael Kerin","tldr":"Professor who is Clinical Director of the Saolta Cancer Managed Clinical Academic Network, the cancer centre serving the west and north west of Ireland from Galway.","route":"/people/michael-kerin/","kind":"person","round":true,"avatar":"person","sub":"Clinical Director, Saolta Cancer Managed Clinical Academic Network (Saolta Cancer MCAN), Galway University Hospitals · University of Galway / Saolta Cancer Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"michael-stratton","name":"Michael Stratton","tldr":"Pioneer of cancer genome sequencing and mutational signatures; led the Cancer Genome Project and formerly directed the Sanger Institute.","route":"/people/michael-stratton/","kind":"person","round":true,"avatar":"person","sub":"Senior Group Leader; former Director · Wellcome Sanger Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"cancer genomics","href":"/tagged/cancer-genomics/","tip":"Every record tagged cancer genomics."},{"label":"mutational signatures","href":"/tagged/mutational-signatures/","tip":"Every record tagged mutational signatures."}]},"sortKeys":{"year":0}},{"id":"michal-mekel","name":"Michal Mekel","tldr":"Endocrine surgeon who leads Rambam Health Care Campus, the largest hospital in northern Israel, after nearly three decades at the institution.","route":"/people/michal-mekel/","kind":"person","round":true,"avatar":"person","sub":"Director General of Rambam Health Care Campus · Rambam Health Care Campus","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"surgery","href":"/tagged/surgery/","tip":"Every record tagged surgery."}]},"sortKeys":{"year":0}},{"id":"michal-mikula","name":"Michał Mikula","tldr":"Molecular geneticist who leads the scientific programme of Poland's National Research Institute of Oncology.","route":"/people/michal-mikula/","kind":"person","round":true,"avatar":"person","sub":"Deputy Director for Scientific Affairs · Maria Skłodowska-Curie National Research Institute of Oncology","facets":{"kind":["Person"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer genetics","href":"/tagged/cancer-genetics/","tip":"Every record tagged cancer genetics."}]},"sortKeys":{"year":0}},{"id":"mohamed-abdel-moaty-samra","name":"Mohamed Abdel Moaty Samra","tldr":"Professor who serves as Dean of the National Cancer Institute at Cairo University, Egypt's national cancer teaching hospital and research institute.","route":"/people/mohamed-abdel-moaty-samra/","kind":"person","round":true,"avatar":"person","sub":"Dean of the National Cancer Institute, Cairo University · National Cancer Institute, Cairo University","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"africa","href":"/tagged/africa/","tip":"Every record tagged africa."}]},"sortKeys":{"year":0}},{"id":"monika-krzyzanowska","name":"Monika Krzyzanowska","tldr":"Medical oncologist and health services researcher who leads the Odette Cancer Program at Sunnybrook in Toronto, one of Canada's largest cancer centres.","route":"/people/monika-krzyzanowska/","kind":"person","round":true,"avatar":"person","sub":"Chief, Odette Cancer Program, Sunnybrook Health Sciences Centre · Sunnybrook Odette Cancer Centre","facets":{"kind":["Person"],"cancers":["Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"medical-oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical-oncology."},{"label":"health-services","href":"/tagged/health-services/","tip":"Every record tagged health-services."}]},"sortKeys":{"year":0}},{"id":"mostafa-aziz-sumon","name":"Mostafa Aziz Sumon","tldr":"Radiation oncologist who directs the National Institute of Cancer Research and Hospital in Dhaka, Bangladesh's only tertiary government hospital dedicated to cancer.","route":"/people/mostafa-aziz-sumon/","kind":"person","round":true,"avatar":"person","sub":"Director (In-charge) and Professor, Radiation Oncology, National Institute of Cancer Research and Hospital, Dhaka · National Institute of Cancer Research and Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"naoto-ueno","name":"Naoto T. Ueno","tldr":"Breast cancer physician-scientist who directs the University of Hawai'i Cancer Center, the NCI-designated cancer centre in Honolulu.","route":"/people/naoto-ueno/","kind":"person","round":true,"avatar":"person","sub":"Director, University of Hawai'i Cancer Center · University of Hawai'i Cancer Center","facets":{"kind":["Person"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"nariaki-matsuura","name":"Nariaki Matsuura","tldr":"President of the Osaka International Cancer Institute, the Osaka prefectural cancer centre that relocated to a new hospital in central Osaka in 2017.","route":"/people/nariaki-matsuura/","kind":"person","round":true,"avatar":"person","sub":"President (Socho), Osaka International Cancer Institute · Osaka International Cancer Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"japan","href":"/tagged/japan/","tip":"Every record tagged japan."}]},"sortKeys":{"year":0}},{"id":"nei-min-chu","name":"Nei-Min Chu","tldr":"Medical oncologist who became President of Taipei's Koo Foundation Sun Yat-Sen Cancer Center in late 2024 after nearly three decades on its staff.","route":"/people/nei-min-chu/","kind":"person","round":true,"avatar":"person","sub":"President (院長) of Koo Foundation Sun Yat-Sen Cancer Center · Koo Foundation Sun Yat-Sen Cancer Center","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"medical-oncology","href":"/tagged/medical-oncology/","tip":"Every record tagged medical-oncology."}]},"sortKeys":{"year":0}},{"id":"nicolaas-schaap","name":"Nicolaas P.M. Schaap","tldr":"Radboudumc haematologist who chairs HOVON, the Dutch-Belgian haemato-oncology cooperative group.","route":"/people/nicolaas-schaap/","kind":"person","round":true,"avatar":"person","sub":"Chair · HOVON","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"stem cell transplantation","href":"/tagged/stem-cell-transplantation/","tip":"Every record tagged stem cell transplantation."}]},"sortKeys":{"year":0}},{"id":"nicolas-penel","name":"Nicolas Penel","tldr":"Medical oncologist and sarcoma specialist who directs Institut Bergonié, the regional cancer centre for Nouvelle-Aquitaine in Bordeaux.","route":"/people/nicolas-penel/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général (Director General) of Institut Bergonié · Institut Bergonié","facets":{"kind":["Person"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"sarcoma","href":"/tagged/sarcoma/","tip":"Every record tagged sarcoma."},{"label":"clinical-trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical-trials."}]},"sortKeys":{"year":0}},{"id":"nicole-concin","name":"Nicole Concin","tldr":"Gynaecologic oncologist who leads Vienna's women's clinic and is first author of the ESGO/ESTRO/ESP endometrial cancer guidelines.","route":"/people/nicole-concin/","kind":"person","round":true,"avatar":"person","sub":"Coordinator, Gynecologic Cancer Unit; Head, Department of Obstetrics and Gynecology · Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","facets":{"kind":["Person"],"cancers":["Endometrial cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gynaecologic oncology","href":"/tagged/gynaecologic-oncology/","tip":"Every record tagged gynaecologic oncology."},{"label":"endometrial cancer","href":"/tagged/endometrial-cancer/","tip":"Every record tagged endometrial cancer."}]},"sortKeys":{"year":0}},{"id":"nikolaus-rajewsky","name":"Nikolaus Rajewsky","tldr":"Systems biologist at the MDC known for microRNA and circular RNA discoveries and for single-cell and spatial genomics applied to cancer.","route":"/people/nikolaus-rajewsky/","kind":"person","logo":"/portraits/nikolaus-rajewsky.jpg","round":true,"avatar":"person","sub":"Group Leader, Systems Biology of Gene Regulatory Elements; Scientific Director, Berlin Institute for Medical Systems Biology (MDC-BIMSB) · Max Delbrück Center for Molecular Medicine","facets":{"kind":["Person"],"cancers":["Triple-negative breast cancer","Non-small-cell lung cancer","Neuroblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."}],"tags":[{"label":"systems biology","href":"/tagged/systems-biology/","tip":"Every record tagged systems biology."},{"label":"genomics","href":"/tagged/genomics/","tip":"Every record tagged genomics."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."}]},"sortKeys":{"year":0}},{"id":"nobuyuki-yamamoto","name":"Nobuyuki Yamamoto","tldr":"Lung cancer specialist at Wakayama Medical University who chairs the West Japan Oncology Group cooperative trials network.","route":"/people/nobuyuki-yamamoto/","kind":"person","round":true,"avatar":"person","sub":"Chairman · West Japan Oncology Group","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"norbert-vey","name":"Norbert Vey","tldr":"Haematologist specialising in leukaemia who has directed Institut Paoli-Calmettes, the Marseille comprehensive cancer centre, since May 2022.","route":"/people/norbert-vey/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général (Director General) of Institut Paoli-Calmettes · Institut Paoli-Calmettes","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia","Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"norman-wolmark","name":"Norman Wolmark","tldr":"Surgical oncologist and long-time Chairman of the NSABP, whose trials established breast-conserving surgery and adjuvant therapy standards in breast and colorectal cancer.","route":"/people/norman-wolmark/","kind":"person","round":true,"avatar":"person","sub":"Chairman · NSABP Foundation","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"oscar-arrieta-rodriguez","name":"Óscar Gerardo Arrieta Rodríguez","tldr":"Medical oncologist specialising in lung cancer who directs Mexico's national cancer institute, INCan, in Mexico City.","route":"/people/oscar-arrieta-rodriguez/","kind":"person","round":true,"avatar":"person","sub":"Director General of the Instituto Nacional de Cancerología (INCan) · Instituto Nacional de Cancerología (Mexico)","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"thoracic-oncology","href":"/tagged/thoracic-oncology/","tip":"Every record tagged thoracic-oncology."}]},"sortKeys":{"year":0}},{"id":"owen-sansom","name":"Owen Sansom","tldr":"Glasgow cancer biologist who directs the CRUK Scotland Institute and is Scientific Director of the CRUK Scotland Centre, known for mouse models of colorectal and pancreatic cancer.","route":"/people/owen-sansom/","kind":"person","round":true,"avatar":"person","sub":"Scientific Director, CRUK Scotland Centre · Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","facets":{"kind":["Person"],"cancers":["Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"colorectal cancer","href":"/tagged/colorectal-cancer/","tip":"Every record tagged colorectal cancer."},{"label":"pancreatic cancer","href":"/tagged/pancreatic-cancer/","tip":"Every record tagged pancreatic cancer."}]},"sortKeys":{"year":0}},{"id":"pamela-kearns","name":"Pamela Kearns","tldr":"Paediatric oncologist and emeritus professor at the University of Birmingham who presides over ITCC, the European consortium for early-phase trials in childhood cancer.","route":"/people/pamela-kearns/","kind":"person","round":true,"avatar":"person","sub":"President, Innovative Therapies for Children with Cancer (ITCC) · Innovative Therapies for Children with Cancer (ITCC)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"professional-society","href":"/tagged/professional-society/","tip":"Every record tagged professional-society."}]},"sortKeys":{"year":0}},{"id":"chaturvedi-pankaj","name":"Pankaj Chaturvedi","tldr":"A surgeon and public-health campaigner whose work links oral cancer to tobacco and drives prevention policy in India.","route":"/people/chaturvedi-pankaj/","kind":"person","round":true,"avatar":"person","sub":"Head and neck surgical oncologist; Director, Centre for Cancer Epidemiology, Tata Memorial Centre · Tata Memorial Centre","facets":{"kind":["Person"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."},{"label":"cancer prevention","href":"/tagged/cancer-prevention/","tip":"Every record tagged cancer prevention."}]},"sortKeys":{"year":0}},{"id":"paola-anna-erba","name":"Paola Anna Erba","tldr":"Italian nuclear medicine physician serving as President of the European Association of Nuclear Medicine.","route":"/people/paola-anna-erba/","kind":"person","logo":"/portraits/paola-anna-erba.jpg","round":true,"avatar":"person","sub":"President (2025-2026) · European Association of Nuclear Medicine","facets":{"kind":["Person"],"cancers":["Neuroendocrine tumours","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"nuclear medicine","href":"/tagged/nuclear-medicine/","tip":"Every record tagged nuclear medicine."},{"label":"theranostics","href":"/tagged/theranostics/","tip":"Every record tagged theranostics."}]},"sortKeys":{"year":0}},{"id":"paris-ann-ingledew","name":"Paris-Ann Ingledew","tldr":"Radiation oncologist and educator who is the executive lead for BC Cancer, the provincial cancer agency of British Columbia, Canada.","route":"/people/paris-ann-ingledew/","kind":"person","round":true,"avatar":"person","sub":"Executive Vice President and Chief Medical Officer, BC Cancer · BC Cancer","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiation-oncology","href":"/tagged/radiation-oncology/","tip":"Every record tagged radiation-oncology."}]},"sortKeys":{"year":0}},{"id":"patrick-morris","name":"Patrick G. Morris","tldr":"Physician who is Medical Director of the Beaumont RCSI Cancer Centre, the OECI accredited cancer centre on the Beaumont Hospital campus in Dublin.","route":"/people/patrick-morris/","kind":"person","round":true,"avatar":"person","sub":"Medical Director, Beaumont RCSI Cancer Centre, Dublin · Beaumont RCSI Cancer Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"patrick-mehlen","name":"Patrick Mehlen","tldr":"Cancer biologist who discovered the dependence-receptor concept and took netrin-1 blockade from bench to clinical trials at Centre Léon Bérard.","route":"/people/patrick-mehlen/","kind":"person","round":true,"avatar":"person","sub":"Director of Fundamental and Translational Research and of the Cancer Research Center of Lyon (CRCL) · Centre Léon Bérard","facets":{"kind":["Person"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer biology","href":"/tagged/cancer-biology/","tip":"Every record tagged cancer biology."},{"label":"drug development","href":"/tagged/drug-development/","tip":"Every record tagged drug development."}]},"sortKeys":{"year":0}},{"id":"paul-boutros","name":"Paul Boutros","tldr":"Computational cancer biologist who directs the NCI-designated Cancer Center at Sanford Burnham Prebys in La Jolla and leads its data sciences work.","route":"/people/paul-boutros/","kind":"person","round":true,"avatar":"person","sub":"Director, NCI-Designated Cancer Center, Sanford Burnham Prebys · Sanford Burnham Prebys Medical Discovery Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"pavan-reddy","name":"Pavan Reddy","tldr":"Physician who directs the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, an NCI-designated comprehensive cancer centre.","route":"/people/pavan-reddy/","kind":"person","round":true,"avatar":"person","sub":"Director, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine · Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"peter-johnson","name":"Peter Johnson","tldr":"Southampton lymphoma specialist who led the RATHL trial of PET-guided therapy in Hodgkin lymphoma and serves as NHS England's National Clinical Director for Cancer.","route":"/people/peter-johnson/","kind":"person","round":true,"avatar":"person","sub":"Professor of Medical Oncology · University Hospital Southampton / Centre for Cancer Immunology","facets":{"kind":["Person"],"cancers":["Hodgkin lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"philip-chiu","name":"Philip Wai Yan Chiu","tldr":"Upper GI surgeon and Dean of the CUHK Faculty of Medicine, the academic home of Prince of Wales Hospital.","route":"/people/philip-chiu/","kind":"person","round":true,"avatar":"person","sub":"Dean, Faculty of Medicine · Prince of Wales Hospital / Chinese University of Hong Kong","facets":{"kind":["Person"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gastric cancer","href":"/tagged/gastric-cancer/","tip":"Every record tagged gastric cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"philippe-bergerot","name":"Philippe Bergerot","tldr":"Radiation oncologist who has presided over the Ligue nationale contre le cancer, France's national cancer charity, since 2024.","route":"/people/philippe-bergerot/","kind":"person","round":true,"avatar":"person","sub":"President of the Ligue nationale contre le cancer (since 2024) · Ligue nationale contre le cancer","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiation-oncology","href":"/tagged/radiation-oncology/","tip":"Every record tagged radiation-oncology."},{"label":"charity","href":"/tagged/charity/","tip":"Every record tagged charity."}]},"sortKeys":{"year":0}},{"id":"pia-vihinen","name":"Pia Vihinen","tldr":"Director who leads FICAN West, the regional cancer centre for western Finland hosted by Turku University Hospital and the Wellbeing services county of Southwest Finland.","route":"/people/pia-vihinen/","kind":"person","round":true,"avatar":"person","sub":"Director (johtaja), FICAN West (Läntinen Syöpäkeskus), Turku University Hospital · Turku University Hospital Cancer Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"pierre-laurent-puig","name":"Pierre Laurent-Puig","tldr":"Oncology professor and Inserm team leader who directs the Institut du Cancer Paris CARPEM, the OECI-accredited comprehensive cancer centre of AP-HP Centre in Paris.","route":"/people/pierre-laurent-puig/","kind":"person","round":true,"avatar":"person","sub":"Director, Institut du Cancer Paris CARPEM and SIRIC CARPEM, AP-HP Centre Université Paris Cité · Institut du Cancer Paris CARPEM, AP-HP Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"pierre-vera","name":"Pierre Vera","tldr":"Nuclear medicine physician who directs Centre Henri Becquerel, the comprehensive cancer centre for the Rouen area in Normandy.","route":"/people/pierre-vera/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général (Director General), Centre Henri Becquerel · Centre Henri Becquerel","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"princess-chulabhorn","name":"Princess Chulabhorn","tldr":"Thai princess and professor of organic chemistry who founded and presides over the Chulabhorn Royal Academy, the parent body of Chulabhorn Hospital in Bangkok.","route":"/people/princess-chulabhorn/","kind":"person","round":true,"avatar":"person","sub":"President of the Chulabhorn Royal Academy Council and Acting Secretary-General · Chulabhorn Hospital / Chulabhorn Royal Academy","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"thailand","href":"/tagged/thailand/","tip":"Every record tagged thailand."}]},"sortKeys":{"year":0}},{"id":"priya-rastogi","name":"Priya Rastogi","tldr":"Pittsburgh medical oncologist who serves as CEO and Medical Director of the NSABP Foundation, leading its breast cancer trial portfolio.","route":"/people/priya-rastogi/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer & Medical Director · NSABP Foundation","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"purnima-sundaresan","name":"Purnima Sundaresan","tldr":"Sydney radiation oncologist who is President of TROG Cancer Research, Australasia's radiation oncology trials group.","route":"/people/purnima-sundaresan/","kind":"person","round":true,"avatar":"person","sub":"President · TROG Cancer Research","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"clinical trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical trials."}]},"sortKeys":{"year":0}},{"id":"r-angelo-de-claro","name":"R. Angelo de Claro","tldr":"Haematologist-oncologist who has directed the FDA's Oncology Center of Excellence since March 2025 and previously led its global clinical sciences programme, including Project Orbis.","route":"/people/r-angelo-de-claro/","kind":"person","round":true,"avatar":"person","sub":"Director, Oncology Center of Excellence, US Food and Drug Administration · FDA Oncology Center of Excellence","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"regulatory","href":"/tagged/regulatory/","tip":"Every record tagged regulatory."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"ralf-c-bargou","name":"Ralf C. Bargou","tldr":"Professor of translational oncology who directs the Comprehensive Cancer Center Mainfranken at University Hospital Würzburg.","route":"/people/ralf-c-bargou/","kind":"person","round":true,"avatar":"person","sub":"Director of the Comprehensive Cancer Center Mainfranken · Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","facets":{"kind":["Person"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer-centre","href":"/tagged/cancer-centre/","tip":"Every record tagged cancer-centre."}]},"sortKeys":{"year":0}},{"id":"ralph-weichselbaum","name":"Ralph Weichselbaum","tldr":"Radiation oncologist at the University of Chicago known for the oligometastasis concept and for research linking radiation with anti-tumour immunity.","route":"/people/ralph-weichselbaum/","kind":"person","round":true,"avatar":"person","sub":"Executive Committee Member · University of Chicago Medicine Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"rana-mckay","name":"Rana McKay","tldr":"Genitourinary medical oncologist at UC San Diego Moores Cancer Center leading clinical science, with a strong trial record in prostate and kidney cancer.","route":"/people/rana-mckay/","kind":"person","round":true,"avatar":"person","sub":"Associate Director, Clinical Science · UC San Diego Moores Cancer Center","facets":{"kind":["Person"],"cancers":["Prostate cancer","Renal cell carcinoma","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[{"label":"prostate cancer","href":"/tagged/prostate-cancer/","tip":"Every record tagged prostate cancer."},{"label":"kidney cancer","href":"/tagged/kidney-cancer/","tip":"Every record tagged kidney cancer."}]},"sortKeys":{"year":0}},{"id":"raymond-dubois","name":"Raymond N. DuBois","tldr":"Physician-scientist known for work on inflammation in gastrointestinal cancers who directs MUSC Hollings Cancer Center, South Carolina's NCI-designated cancer centre.","route":"/people/raymond-dubois/","kind":"person","round":true,"avatar":"person","sub":"Director, MUSC Hollings Cancer Center, and Associate Provost for Cancer Programs, Medical University of South Carolina · MUSC Hollings Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"rebecca-auer","name":"Rebecca Auer","tldr":"Cancer surgeon and scientist who leads research and innovation at The Ottawa Hospital and its research institute.","route":"/people/rebecca-auer/","kind":"person","round":true,"avatar":"person","sub":"Executive Vice-President, Research and Innovation, The Ottawa Hospital / Ottawa Hospital Research Institute · The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute","facets":{"kind":["Person"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"surgical-oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical-oncology."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."}]},"sortKeys":{"year":0}},{"id":"rebecca-dent","name":"Rebecca Dent","tldr":"Breast medical oncologist and Deputy CEO for clinical operations at the National Cancer Centre Singapore, an international leader in triple-negative breast cancer trials.","route":"/people/rebecca-dent/","kind":"person","round":true,"avatar":"person","sub":"Deputy Chief Executive Officer (Clinical) · National Cancer Centre Singapore","facets":{"kind":["Person"],"cancers":["Triple-negative breast cancer","HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."}]},"sortKeys":{"year":0}},{"id":"renaud-de-crevoisier","name":"Renaud de Crevoisier","tldr":"Professor of medicine who directs Centre Eugène Marquis, the regional comprehensive cancer centre for Brittany in Rennes.","route":"/people/renaud-de-crevoisier/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général (Director General), Centre Eugène Marquis · Centre Eugène Marquis","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"rene-medema","name":"René Medema","tldr":"Cancer biologist and former head of the Netherlands Cancer Institute who sits on the three-member executive board of the Princess Máxima Center as Chief Scientific Officer.","route":"/people/rene-medema/","kind":"person","round":true,"avatar":"person","sub":"Chief Scientific Officer and member of the Raad van Bestuur, Prinses Máxima Centrum voor kinderoncologie · Princess Máxima Center for Pediatric Oncology","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"reuben-shaw","name":"Reuben Shaw","tldr":"Cancer biologist who directs the NCI-designated Salk Cancer Center in La Jolla and holds the William R. Brody Chair at the Salk Institute.","route":"/people/reuben-shaw/","kind":"person","round":true,"avatar":"person","sub":"Director of the Salk Cancer Center, Salk Institute for Biological Studies · Salk Institute Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"richard-barakat","name":"Richard Barakat","tldr":"Physician-in-Chief and Executive Director of the Northwell Cancer Institute, the cancer service of New York's largest health system.","route":"/people/richard-barakat/","kind":"person","round":true,"avatar":"person","sub":"Physician-in-Chief and Executive Director, Northwell Cancer Institute · Northwell Health Cancer Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"health-system","href":"/tagged/health-system/","tip":"Every record tagged health-system."}]},"sortKeys":{"year":0}},{"id":"richard-schulick","name":"Richard Schulick","tldr":"Pancreatic cancer surgeon who has directed the University of Colorado Cancer Center, the state's NCI-designated comprehensive cancer centre, since 2018.","route":"/people/richard-schulick/","kind":"person","round":true,"avatar":"person","sub":"Director · University of Colorado Cancer Center","facets":{"kind":["Person"],"cancers":["Pancreatic ductal adenocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"pancreatic cancer","href":"/tagged/pancreatic-cancer/","tip":"Every record tagged pancreatic cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"richard-van-etten","name":"Richard Van Etten","tldr":"Physician-scientist who directs the Chao Family Comprehensive Cancer Center at UC Irvine, the NCI-designated comprehensive cancer centre for Orange County.","route":"/people/richard-van-etten/","kind":"person","round":true,"avatar":"person","sub":"Director, Chao Family Comprehensive Cancer Center, University of California, Irvine · Chao Family Comprehensive Cancer Center, UC Irvine","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"rita-schmutzler","name":"Rita Schmutzler","tldr":"Gynaecological oncologist and hereditary cancer expert who became President of Deutsche Krebshilfe, Germany's largest cancer charity, in 2026.","route":"/people/rita-schmutzler/","kind":"person","logo":"/portraits/rita-schmutzler.jpg","round":true,"avatar":"person","sub":"Präsidentin of the Stiftung Deutsche Krebshilfe (2026-) · Deutsche Krebshilfe","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","Triple-negative breast cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"charity","href":"/tagged/charity/","tip":"Every record tagged charity."},{"label":"hereditary-cancer","href":"/tagged/hereditary-cancer/","tip":"Every record tagged hereditary-cancer."}]},"sortKeys":{"year":0}},{"id":"robert-winn","name":"Robert A. Winn","tldr":"Physician who leads VCU Massey Comprehensive Cancer Center in Richmond, Virginia, the NCI-designated comprehensive cancer centre of Virginia Commonwealth University.","route":"/people/robert-winn/","kind":"person","logo":"/portraits/robert-winn.jpg","round":true,"avatar":"person","sub":"Director, VCU Massey Comprehensive Cancer Center · VCU Massey Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"robert-figlin","name":"Robert Figlin","tldr":"Medical oncologist who has led Cedars-Sinai Cancer in Los Angeles as Interim Director since March 2025.","route":"/people/robert-figlin/","kind":"person","round":true,"avatar":"person","sub":"Interim Director of Cedars-Sinai Cancer · Cedars-Sinai Cancer","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer-centre","href":"/tagged/cancer-centre/","tip":"Every record tagged cancer-centre."}]},"sortKeys":{"year":0}},{"id":"robert-negrin","name":"Robert Negrin","tldr":"Stanford transplant physician and cellular immunologist who is President of the American Society of Hematology for 2026.","route":"/people/robert-negrin/","kind":"person","round":true,"avatar":"person","sub":"President of the American Society of Hematology (2026) · American Society of Hematology","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"society","href":"/tagged/society/","tip":"Every record tagged society."}]},"sortKeys":{"year":0}},{"id":"robert-peel","name":"Robert Peel","tldr":"Kidney specialist from NHS Highland who chairs the Scottish Medicines Consortium, the body that decides which newly licensed medicines are accepted for use in the Scottish health service.","route":"/people/robert-peel/","kind":"person","round":true,"avatar":"person","sub":"Chair of the Scottish Medicines Consortium · Scottish Medicines Consortium","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"health-technology-assessment","href":"/tagged/health-technology-assessment/","tip":"Every record tagged health-technology-assessment."},{"label":"drug-reimbursement","href":"/tagged/drug-reimbursement/","tip":"Every record tagged drug-reimbursement."}]},"sortKeys":{"year":0}},{"id":"robert-langer","name":"Robert S. Langer","tldr":"Biomedical engineer whose Koch Institute lab pioneered controlled drug delivery and nanomedicine, including approaches to cancer therapy.","route":"/people/robert-langer/","kind":"person","logo":"/portraits/robert-langer.jpg","round":true,"avatar":"person","sub":"David H. Koch (1962) Institute Professor · David H. Koch Institute for Integrative Cancer Research at MIT","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"drug delivery","href":"/tagged/drug-delivery/","tip":"Every record tagged drug delivery."},{"label":"nanomedicine","href":"/tagged/nanomedicine/","tip":"Every record tagged nanomedicine."}]},"sortKeys":{"year":0}},{"id":"robert-mannel","name":"Robert S. Mannel","tldr":"Oklahoma gynecologic oncologist and Senior Vice President of the GOG Foundation.","route":"/people/robert-mannel/","kind":"person","round":true,"avatar":"person","sub":"Senior Vice President · GOG Foundation","facets":{"kind":["Person"],"cancers":["Ovarian cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gynecologic oncology","href":"/tagged/gynecologic-oncology/","tip":"Every record tagged gynecologic oncology."}]},"sortKeys":{"year":0}},{"id":"robyn-ward","name":"Robyn Ward","tldr":"Medical oncologist and cancer geneticist who chairs the independent expert committee that recommends which medicines Australia subsidises through the Pharmaceutical Benefits Scheme.","route":"/people/robyn-ward/","kind":"person","logo":"/portraits/robyn-ward.jpg","round":true,"avatar":"person","sub":"Chair of the Pharmaceutical Benefits Advisory Committee · Pharmaceutical Benefits Advisory Committee","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"health-technology-assessment","href":"/tagged/health-technology-assessment/","tip":"Every record tagged health-technology-assessment."},{"label":"drug-reimbursement","href":"/tagged/drug-reimbursement/","tip":"Every record tagged drug-reimbursement."}]},"sortKeys":{"year":0}},{"id":"rohit-bhargava","name":"Rohit Bhargava","tldr":"Engineer who founded and directs the Cancer Center at Illinois, the University of Illinois Urbana-Champaign centre that applies engineering and basic science to cancer.","route":"/people/rohit-bhargava/","kind":"person","round":true,"avatar":"person","sub":"Phillip and Ann Sharp Director, Cancer Center at Illinois · Cancer Center at Illinois","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"roman-rouzier","name":"Roman Rouzier","tldr":"Gynaecological and breast surgeon who has directed Centre François Baclesse, the comprehensive cancer centre for Normandy in Caen, since July 2023.","route":"/people/roman-rouzier/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général (Director General), Centre François Baclesse · Centre François Baclesse","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"ruben-mesa","name":"Ruben Mesa","tldr":"Physician who is Executive Director of the NCI-designated Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem and President of its cancer service line.","route":"/people/ruben-mesa/","kind":"person","round":true,"avatar":"person","sub":"Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, and President of the Cancer Service Line · Atrium Health Wake Forest Baptist Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"ryan-schoenfeld","name":"Ryan Schoenfeld","tldr":"Medicinal chemist who leads The Mark Foundation for Cancer Research, a funder that turns laboratory discoveries into new cancer tests and treatments.","route":"/people/ryan-schoenfeld/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer, The Mark Foundation for Cancer Research · The Mark Foundation for Cancer Research","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"drug-discovery","href":"/tagged/drug-discovery/","tip":"Every record tagged drug-discovery."},{"label":"research-funding","href":"/tagged/research-funding/","tip":"Every record tagged research-funding."}]},"sortKeys":{"year":0}},{"id":"samra-turajlic","name":"Samra Turajlić","tldr":"Medical oncologist and cancer-evolution researcher who leads the TRACERx Renal study and now directs the Cancer Research UK Manchester Institute.","route":"/people/samra-turajlic/","kind":"person","round":true,"avatar":"person","sub":"Director · Cancer Research UK Manchester Institute","facets":{"kind":["Person"],"cancers":["Renal cell carcinoma","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"kidney cancer","href":"/tagged/kidney-cancer/","tip":"Every record tagged kidney cancer."},{"label":"cancer evolution","href":"/tagged/cancer-evolution/","tip":"Every record tagged cancer evolution."}]},"sortKeys":{"year":0}},{"id":"sandra-demaria","name":"Sandra Demaria","tldr":"Weill Cornell pathologist-immunologist known for radiation-immunotherapy research; SITC Vice President.","route":"/people/sandra-demaria/","kind":"person","round":true,"avatar":"person","sub":"Vice President (2025-2026) · Society for Immunotherapy of Cancer","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunotherapy","href":"/tagged/immunotherapy/","tip":"Every record tagged immunotherapy."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."}]},"sortKeys":{"year":0}},{"id":"sandra-nolte","name":"Sandra Nolte","tldr":"Monash University researcher who is President of the international society for health-related quality of life research for the 2025 to 2027 term.","route":"/people/sandra-nolte/","kind":"person","round":true,"avatar":"person","sub":"President (2025-2027), International Society for Quality of Life Research · International Society for Quality of Life Research","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"quality-of-life","href":"/tagged/quality-of-life/","tip":"Every record tagged quality-of-life."},{"label":"patient-reported-outcomes","href":"/tagged/patient-reported-outcomes/","tip":"Every record tagged patient-reported-outcomes."}]},"sortKeys":{"year":0}},{"id":"sara-brucker","name":"Sara Y. Brucker","tldr":"Gynaecologist who co-leads the CCC Tübingen-Stuttgart and directs women's health at Tübingen University Hospital, with research in breast and gynaecological cancers.","route":"/people/sara-brucker/","kind":"person","round":true,"avatar":"person","sub":"Deputy Speaker; Medical Director, Department for Women's Health · Comprehensive Cancer Center Tübingen-Stuttgart","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","Endometrial cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"gynaecological oncology","href":"/tagged/gynaecological-oncology/","tip":"Every record tagged gynaecological oncology."}]},"sortKeys":{"year":0}},{"id":"sascha-dietrich","name":"Sascha Dietrich","tldr":"Haematologist-oncologist and Deputy Medical Director at University Hospital Düsseldorf, known for drug-response profiling in lymphoma and leukaemia.","route":"/people/sascha-dietrich/","kind":"person","round":true,"avatar":"person","sub":"Deputy Medical Director · University Hospital Düsseldorf / CIO Düsseldorf","facets":{"kind":["Person"],"cancers":["Chronic lymphocytic leukaemia","Hairy cell leukaemia","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Hairy cell leukaemia","href":"/cancers/hairy-cell-leukemia/","tip":"Hairy cell leukaemia is a rare, slow B-cell leukaemia with a single defining mutation (BRAF V600E) that is unusually curable: one week of a purine analogue puts most people into remission for years, and BRAF drugs rescue those who relapse."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."}]},"sortKeys":{"year":0}},{"id":"satu-tiainen","name":"Satu Tiainen","tldr":"Chief physician who directs Itäinen syöpäkeskus, the FICAN East regional cancer centre hosted by Kuopio University Hospital and the Pohjois-Savo wellbeing services county.","route":"/people/satu-tiainen/","kind":"person","round":true,"avatar":"person","sub":"Ylilääkäri and Johtaja (Chief Physician and Director), Itäinen syöpäkeskus (FICAN East), Kuopio University Hospital · Kuopio University Hospital Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"senthil-muthuswamy","name":"Senthil K. Muthuswamy","tldr":"Cancer biologist who directs the National Cancer Institute's Center for Cancer Research, the large intramural research programme in Bethesda.","route":"/people/senthil-muthuswamy/","kind":"person","round":true,"avatar":"person","sub":"Director, Center for Cancer Research, National Cancer Institute · NCI Center for Cancer Research (intramural programme)","facets":{"kind":["Person"],"cancers":["Pancreatic ductal adenocarcinoma","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"cancer-biology","href":"/tagged/cancer-biology/","tip":"Every record tagged cancer-biology."},{"label":"organoids","href":"/tagged/organoids/","tip":"Every record tagged organoids."}]},"sortKeys":{"year":0}},{"id":"seyed-rouhollah-miri","name":"Seyed Rouhollah Miri","tldr":"Surgical oncologist who heads the Cancer Institute of Iran at Tehran's Imam Khomeini Hospital Complex, the country's oldest dedicated cancer institute.","route":"/people/seyed-rouhollah-miri/","kind":"person","round":true,"avatar":"person","sub":"Head of the Cancer Institute, Imam Khomeini Hospital Complex · Cancer Institute of Iran, Imam Khomeini Hospital Complex","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"surgical-oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical-oncology."}]},"sortKeys":{"year":0}},{"id":"shahrokh-f-shariat","name":"Shahrokh F. Shariat","tldr":"Prolific urologic oncologist who chairs Vienna's Department of Urology and leads the Comprehensive Cancer Center of MedUni Wien and AKH.","route":"/people/shahrokh-f-shariat/","kind":"person","logo":"/portraits/shahrokh-f-shariat.jpg","round":true,"avatar":"person","sub":"Head of the Comprehensive Cancer Center Vienna; Head, Department of Urology · Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","facets":{"kind":["Person"],"cancers":["Bladder & urothelial cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"urologic oncology","href":"/tagged/urologic-oncology/","tip":"Every record tagged urologic oncology."},{"label":"bladder cancer","href":"/tagged/bladder-cancer/","tip":"Every record tagged bladder cancer."},{"label":"oeci-representative","href":"/tagged/oeci-representative/","tip":"Every record tagged oeci-representative."}]},"sortKeys":{"year":0}},{"id":"shivaani-kummar","name":"Shivaani Kummar","tldr":"Drug development oncologist who directs the OHSU Knight Cancer Institute.","route":"/people/shivaani-kummar/","kind":"person","round":true,"avatar":"person","sub":"Chief Scientific and Academic Officer, Knight Cancer Group and Director, Knight Cancer Institute · OHSU Knight Cancer Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"drug development","href":"/tagged/drug-development/","tip":"Every record tagged drug development."},{"label":"precision oncology","href":"/tagged/precision-oncology/","tip":"Every record tagged precision oncology."}]},"sortKeys":{"year":0}},{"id":"shlomi-codish","name":"Shlomi Codish","tldr":"Internal medicine physician and medical informatics specialist who leads Soroka University Medical Center in Beersheba, the largest hospital in southern Israel.","route":"/people/shlomi-codish/","kind":"person","logo":"/portraits/shlomi-codish.jpg","round":true,"avatar":"person","sub":"Director General, Soroka University Medical Center · Soroka University Medical Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"lu-shun","name":"Shun Lu","tldr":"A Shanghai lung cancer trialist who has led many Chinese PD-1 and EGFR-TKI phase 3 studies.","route":"/people/lu-shun/","kind":"person","round":true,"avatar":"person","sub":"Professor; Director, Shanghai Lung Cancer Center, Shanghai Chest Hospital · Shanghai Chest Hospital","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"targeted therapy","href":"/tagged/targeted-therapy/","tip":"Every record tagged targeted therapy."}]},"sortKeys":{"year":0}},{"id":"silvana-konermann","name":"Silvana Konermann","tldr":"Neuroscientist and co-founder who runs the Arc Institute, an independent research institute in the San Francisco Bay Area built to tackle complex diseases.","route":"/people/silvana-konermann/","kind":"person","round":true,"avatar":"person","sub":"Executive Director and Core Investigator, Arc Institute · Arc Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"genomics","href":"/tagged/genomics/","tip":"Every record tagged genomics."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"sirpa-leppa","name":"Sirpa Leppä","tldr":"Helsinki oncologist who chairs the Nordic Lymphoma Group, the cooperative network that runs lymphoma trials and guidelines across the Nordic countries.","route":"/people/sirpa-leppa/","kind":"person","round":true,"avatar":"person","sub":"Chairperson, Nordic Lymphoma Group · Nordic Lymphoma Group","facets":{"kind":["Person"],"cancers":["Diffuse large B-cell lymphoma","Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."},{"label":"cooperative-group","href":"/tagged/cooperative-group/","tip":"Every record tagged cooperative-group."}]},"sortKeys":{"year":0}},{"id":"stanislaw-klek","name":"Stanislaw Klek","tldr":"Chairman of the European Society for Clinical Nutrition and Metabolism, the society that issues Europe's clinical nutrition guidelines, including those for people with cancer.","route":"/people/stanislaw-klek/","kind":"person","round":true,"avatar":"person","sub":"Chairman of ESPEN (term until 2028) · European Society for Clinical Nutrition and Metabolism","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"nutrition","href":"/tagged/nutrition/","tip":"Every record tagged nutrition."},{"label":"society","href":"/tagged/society/","tip":"Every record tagged society."}]},"sortKeys":{"year":0}},{"id":"stephen-scherer","name":"Stephen Scherer","tldr":"Genome scientist who heads research at SickKids and co-discovered genome-wide copy number variation in humans.","route":"/people/stephen-scherer/","kind":"person","logo":"/portraits/stephen-scherer.jpg","round":true,"avatar":"person","sub":"Chief of Research · The Hospital for Sick Children (SickKids)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"genomics","href":"/tagged/genomics/","tip":"Every record tagged genomics."}]},"sortKeys":{"year":0}},{"id":"steven-clifford","name":"Steven Clifford","tldr":"Medulloblastoma biologist whose molecular subgrouping work underpins risk-adapted treatment of childhood brain tumours; directs Newcastle University's cancer centre.","route":"/people/steven-clifford/","kind":"person","round":true,"avatar":"person","sub":"Chair of Molecular Paediatric Oncology and Director, Newcastle University Centre for Cancer · Newcastle Cancer Centre / Northern Centre for Cancer Care","facets":{"kind":["Person"],"cancers":["Medulloblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Medulloblastoma","href":"/cancers/medulloblastoma/","tip":"Medulloblastoma is the most common malignant childhood brain tumour, arising in the cerebellum. Surgery, radiation to the whole brain and spine, and chemotherapy cure about 70%, at a heavy cost to thinking and growth; treatment is now being tailored to four molecular subgroups so that the low-risk children get less."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"paediatric oncology","href":"/tagged/paediatric-oncology/","tip":"Every record tagged paediatric oncology."},{"label":"neuro-oncology","href":"/tagged/neuro-oncology/","tip":"Every record tagged neuro-oncology."}]},"sortKeys":{"year":0}},{"id":"steven-k-libutti","name":"Steven K. Libutti","tldr":"Surgeon who directs Rutgers Cancer Institute of New Jersey, the state's NCI-designated comprehensive cancer centre.","route":"/people/steven-k-libutti/","kind":"person","logo":"/portraits/steven-k-libutti.jpg","round":true,"avatar":"person","sub":"Director, Rutgers Cancer Institute of New Jersey · Rutgers Cancer Institute of New Jersey","facets":{"kind":["Person"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"sunil-lakhani","name":"Sunil Lakhani","tldr":"Brisbane breast pathologist who chairs the board of Breast Cancer Trials, the Australia and New Zealand breast cancer clinical trials group.","route":"/people/sunil-lakhani/","kind":"person","round":true,"avatar":"person","sub":"Chair of the Board · Breast Cancer Trials","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"pathology","href":"/tagged/pathology/","tip":"Every record tagged pathology."}]},"sortKeys":{"year":0}},{"id":"suresh-ramalingam","name":"Suresh S. Ramalingam","tldr":"Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib.","route":"/people/suresh-ramalingam/","kind":"person","round":true,"avatar":"person","sub":"Executive Director · Winship Cancer Institute of Emory University","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"targeted therapy","href":"/tagged/targeted-therapy/","tip":"Every record tagged targeted therapy."}]},"sortKeys":{"year":0}},{"id":"susan-msadabwe","name":"Susan C. Msadabwe","tldr":"Physician who runs the Cancer Diseases Hospital in Lusaka, Zambia's national cancer treatment hospital, as its Senior Medical Superintendent.","route":"/people/susan-msadabwe/","kind":"person","round":true,"avatar":"person","sub":"Senior Medical Superintendent, Cancer Diseases Hospital, Lusaka · Cancer Diseases Hospital, Lusaka","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"susan-clark","name":"Susan Clark","tldr":"Pioneer of DNA methylation analysis whose Garvan laboratory studies how epigenetic changes drive prostate and breast cancer.","route":"/people/susan-clark/","kind":"person","logo":"/portraits/susan-clark.jpg","round":true,"avatar":"person","sub":"Head of the Cancer Epigenetics Laboratory · Garvan Institute of Medical Research / Kinghorn Cancer Centre","facets":{"kind":["Person"],"cancers":["Prostate cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[{"label":"epigenetics","href":"/tagged/epigenetics/","tip":"Every record tagged epigenetics."},{"label":"prostate cancer","href":"/tagged/prostate-cancer/","tip":"Every record tagged prostate cancer."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."}]},"sortKeys":{"year":0}},{"id":"susan-furth","name":"Susan Furth","tldr":"Paediatric nephrologist and Chief Scientific Officer of Children's Hospital of Philadelphia, overseeing its research institute including paediatric cancer research.","route":"/people/susan-furth/","kind":"person","round":true,"avatar":"person","sub":"Chief Scientific Officer · Children's Hospital of Philadelphia","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"paediatrics","href":"/tagged/paediatrics/","tip":"Every record tagged paediatrics."}]},"sortKeys":{"year":0}},{"id":"susana-puig","name":"Susana Puig","tldr":"Dermatologist and melanoma researcher who directs IDIBAPS, the research institute of Hospital Clínic de Barcelona.","route":"/people/susana-puig/","kind":"person","round":true,"avatar":"person","sub":"Director, IDIBAPS · Hospital Clínic de Barcelona / IDIBAPS","facets":{"kind":["Person"],"cancers":["Melanoma","Basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"melanoma","href":"/tagged/melanoma/","tip":"Every record tagged melanoma."}]},"sortKeys":{"year":0}},{"id":"suzette-delaloge","name":"Suzette Delaloge","tldr":"Breast medical oncologist from Gustave Roussy who chairs the board of France's Institut National du Cancer.","route":"/people/suzette-delaloge/","kind":"person","logo":"/portraits/suzette-delaloge.jpg","round":true,"avatar":"person","sub":"Chair of the Board of Directors · Institut National du Cancer","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."},{"label":"cancer policy","href":"/tagged/cancer-policy/","tip":"Every record tagged cancer policy."}]},"sortKeys":{"year":0}},{"id":"yoshino-takayuki","name":"Takayuki Yoshino","tldr":"Leads CIRCULATE-Japan, the largest ctDNA-guided adjuvant programme in colorectal cancer, and the PARADIGM and SCRUM-Japan GI efforts.","route":"/people/yoshino-takayuki/","kind":"person","round":true,"avatar":"person","sub":"Chief, Department of Gastroenterology and GI Oncology, National Cancer Center Hospital East; President, Japanese Society of Medical Oncology · National Cancer Center Hospital","facets":{"kind":["Person"],"cancers":["Colorectal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"colorectal cancer","href":"/tagged/colorectal-cancer/","tip":"Every record tagged colorectal cancer."},{"label":"precision oncology","href":"/tagged/precision-oncology/","tip":"Every record tagged precision oncology."}]},"sortKeys":{"year":0}},{"id":"tammy-kang","name":"Tammy Kang","tldr":"Paediatric oncologist and palliative care physician serving as Interim Director of Texas Children's Cancer and Hematology Center.","route":"/people/tammy-kang/","kind":"person","round":true,"avatar":"person","sub":"Interim Director · Texas Children's Cancer and Hematology Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"paediatric oncology","href":"/tagged/paediatric-oncology/","tip":"Every record tagged paediatric oncology."}]},"sortKeys":{"year":0}},{"id":"tan-weihong","name":"Tan Weihong","tldr":"Chinese Academy of Sciences academician who is President of Zhejiang Cancer Hospital in Hangzhou and director of the CAS Hangzhou Institute of Medicine.","route":"/people/tan-weihong/","kind":"person","round":true,"avatar":"person","sub":"President (院长) of Zhejiang Cancer Hospital · Zhejiang Cancer Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"taofeek-owonikoko","name":"Taofeek K. Owonikoko","tldr":"Medical oncologist who is Executive Director of the NCI-designated Greenebaum Comprehensive Cancer Center at the University of Maryland in Baltimore.","route":"/people/taofeek-owonikoko/","kind":"person","round":true,"avatar":"person","sub":"Executive Director, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center · University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"tari-king","name":"Tari A. King","tldr":"Breast surgical oncologist at Winship Cancer Institute and President-Elect of the Society of Surgical Oncology, known for research on lobular breast cancer and surgical de-escalation.","route":"/people/tari-king/","kind":"person","round":true,"avatar":"person","sub":"President-Elect · Society of Surgical Oncology","facets":{"kind":["Person"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."},{"label":"breast cancer","href":"/tagged/breast-cancer/","tip":"Every record tagged breast cancer."}]},"sortKeys":{"year":0}},{"id":"tariq-enver","name":"Tariq Enver","tldr":"Scientist who directs the Cancer Research UK City of London Centre, the multi-institution London hub for cancer biotherapeutics research.","route":"/people/tariq-enver/","kind":"person","round":true,"avatar":"person","sub":"Director, Cancer Research UK City of London Centre · Cancer Research UK City of London Centre","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"research-institute","href":"/tagged/research-institute/","tip":"Every record tagged research-institute."}]},"sortKeys":{"year":0}},{"id":"tatsuya-ohno","name":"Tatsuya Ohno","tldr":"Carbon-ion radiotherapy specialist who directs the Gunma University Heavy Ion Medical Center, Japan's first university-based carbon-ion cancer treatment facility.","route":"/people/tatsuya-ohno/","kind":"person","round":true,"avatar":"person","sub":"Director of the Gunma University Heavy Ion Medical Center · Gunma University Heavy Ion Medical Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"particle-therapy","href":"/tagged/particle-therapy/","tip":"Every record tagged particle-therapy."}]},"sortKeys":{"year":0}},{"id":"theodore-levin","name":"Theodore R. Levin","tldr":"Gastroenterologist who leads cancer research at Kaiser Permanente's Division of Research and is a leading figure in colorectal cancer screening.","route":"/people/theodore-levin/","kind":"person","round":true,"avatar":"person","sub":"Associate Director, Cancer · Kaiser Permanente Division of Research","facets":{"kind":["Person"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"colorectal cancer","href":"/tagged/colorectal-cancer/","tip":"Every record tagged colorectal cancer."},{"label":"screening","href":"/tagged/screening/","tip":"Every record tagged screening."}]},"sortKeys":{"year":0}},{"id":"thomas-herzog","name":"Thomas Herzog","tldr":"Cincinnati gynecologic oncologist who has led the GOG Foundation as President since July 2023.","route":"/people/thomas-herzog/","kind":"person","round":true,"avatar":"person","sub":"President · GOG Foundation","facets":{"kind":["Person"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gynecologic oncology","href":"/tagged/gynecologic-oncology/","tip":"Every record tagged gynecologic oncology."},{"label":"ovarian cancer","href":"/tagged/ovarian-cancer/","tip":"Every record tagged ovarian cancer."}]},"sortKeys":{"year":0}},{"id":"thomas-george","name":"Thomas J. George","tldr":"Oncologist (FACP, FASCO) who is Interim Director of the UF Health Cancer Institute in Gainesville, Florida's only NCI-designated cancer centre based at a public university.","route":"/people/thomas-george/","kind":"person","round":true,"avatar":"person","sub":"Interim Director, UF Health Cancer Institute (University of Florida Health Cancer Center) · University of Florida Health Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"thomas-kindler","name":"Thomas Kindler","tldr":"Haematologist-oncologist who directs the University Cancer Center Mainz at Universitätsmedizin Mainz.","route":"/people/thomas-kindler/","kind":"person","round":true,"avatar":"person","sub":"Director · University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"thomas-loughran","name":"Thomas P. Loughran Jr.","tldr":"Director who leads the UVA Comprehensive Cancer Center in Charlottesville, Virginia's first NCI-designated comprehensive cancer centre.","route":"/people/thomas-loughran/","kind":"person","logo":"/portraits/thomas-loughran.jpg","round":true,"avatar":"person","sub":"Director, UVA Comprehensive Cancer Center · UVA Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"tim-somervaille","name":"Tim Somervaille","tldr":"Haematologist and Senior Group Leader at CRUK Manchester Institute studying the transcriptional drivers of acute myeloid leukaemia.","route":"/people/tim-somervaille/","kind":"person","round":true,"avatar":"person","sub":"Senior Group Leader · Cancer Research UK Manchester Institute","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"leukaemia","href":"/tagged/leukaemia/","tip":"Every record tagged leukaemia."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"tomas-kazda","name":"Tomáš Kazda","tldr":"Radiation oncologist directing science and research at Masaryk Memorial Cancer Institute, with a research focus on brain tumours and brain metastases.","route":"/people/tomas-kazda/","kind":"person","round":true,"avatar":"person","sub":"Director for Science & Research · Masaryk Memorial Cancer Institute","facets":{"kind":["Person"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"radiotherapy","href":"/tagged/radiotherapy/","tip":"Every record tagged radiotherapy."},{"label":"neuro-oncology","href":"/tagged/neuro-oncology/","tip":"Every record tagged neuro-oncology."}]},"sortKeys":{"year":0}},{"id":"tony-mok","name":"Tony S. K. Mok","tldr":"Lung cancer pioneer whose IPASS trial established EGFR-targeted therapy as first-line treatment; chairs Clinical Oncology at CUHK.","route":"/people/tony-mok/","kind":"person","round":true,"avatar":"person","sub":"Chairman, Department of Clinical Oncology; Li Shu Fan Professor of Clinical Oncology · Prince of Wales Hospital / Chinese University of Hong Kong","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"precision oncology","href":"/tagged/precision-oncology/","tip":"Every record tagged precision oncology."}]},"sortKeys":{"year":0}},{"id":"doi-toshihiko","name":"Toshihiko Doi","tldr":"Led the first-in-human study of trastuzumab deruxtecan and runs one of Asia's most productive phase 1 units.","route":"/people/doi-toshihiko/","kind":"person","round":true,"avatar":"person","sub":"Director, Department of Experimental Therapeutics, National Cancer Center Hospital East · National Cancer Center Hospital","facets":{"kind":["Person"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gastric cancer","href":"/tagged/gastric-cancer/","tip":"Every record tagged gastric cancer."},{"label":"drug development","href":"/tagged/drug-development/","tip":"Every record tagged drug development."}]},"sortKeys":{"year":0}},{"id":"ulrich-steidl","name":"Ulrich G. Steidl","tldr":"Physician-scientist who directs the Montefiore Einstein Comprehensive Cancer Center, the NCI-designated cancer centre serving the Bronx and surrounding New York communities.","route":"/people/ulrich-steidl/","kind":"person","round":true,"avatar":"person","sub":"Director, Montefiore Einstein Comprehensive Cancer Center · Montefiore Einstein Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"uta-dirksen","name":"Uta Dirksen","tldr":"Paediatric oncologist from University Hospital Essen who presides over SIOP Europe and has led international Ewing sarcoma trials.","route":"/people/uta-dirksen/","kind":"person","round":true,"avatar":"person","sub":"President · SIOP Europe (European Society for Paediatric Oncology)","facets":{"kind":["Person"],"cancers":["Ewing sarcoma","Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ewing sarcoma","href":"/cancers/ewing-sarcoma/","tip":"Ewing sarcoma is a bone and soft-tissue cancer of teenagers driven by a single fusion gene, EWSR1-FLI1. Intensive chemotherapy with surgery or radiation cures most localised cases; disease that has spread at diagnosis, and relapse, remain hard to treat, and no drug against the fusion protein itself has yet succeeded."},{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"paediatric oncology","href":"/tagged/paediatric-oncology/","tip":"Every record tagged paediatric oncology."},{"label":"sarcoma","href":"/tagged/sarcoma/","tip":"Every record tagged sarcoma."}]},"sortKeys":{"year":0}},{"id":"valery-lemmens","name":"Valery Lemmens","tldr":"Cancer epidemiologist and professor who became Director of OncoZON, the oncology network of ten hospitals in the south-east Netherlands, in August 2026.","route":"/people/valery-lemmens/","kind":"person","round":true,"avatar":"person","sub":"Director, OncoZON (regional oncology network, south-east Netherlands) · OncoZON Comprehensive Cancer Network","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"comprehensive-cancer-centre","href":"/tagged/comprehensive-cancer-centre/","tip":"Every record tagged comprehensive-cancer-centre."}]},"sortKeys":{"year":0}},{"id":"vasanta-nanduri","name":"Vasanta Nanduri","tldr":"Clinician at Watford General Hospital who is President of the Histiocyte Society, the international research society for histiocytic disorders, for the 2025 to 2028 term.","route":"/people/vasanta-nanduri/","kind":"person","round":true,"avatar":"person","sub":"President, Histiocyte Society · Histiocyte Society","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"professional-society","href":"/tagged/professional-society/","tip":"Every record tagged professional-society."}]},"sortKeys":{"year":0}},{"id":"victor-hugo-borja-aburto","name":"Víctor Hugo Borja Aburto","tldr":"Epidemiologist who heads COFEPRIS, Mexico's federal regulator for medicines, medical devices and other health risks.","route":"/people/victor-hugo-borja-aburto/","kind":"person","round":true,"avatar":"person","sub":"Comisionado Federal para la Protección contra Riesgos Sanitarios (2026-) · Comisión Federal para la Protección contra Riesgos Sanitarios","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"regulator","href":"/tagged/regulator/","tip":"Every record tagged regulator."}]},"sortKeys":{"year":0}},{"id":"wang-ying","name":"Wang Ying","tldr":"Radiation oncologist who is President of Chongqing University Cancer Hospital, the tertiary cancer hospital and regional cancer centre for Chongqing.","route":"/people/wang-ying/","kind":"person","round":true,"avatar":"person","sub":"President (院长) and Deputy Party Secretary, Chongqing University Cancer Hospital · Chongqing University Cancer Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"wasiu-lanre-adeyemo","name":"Wasiu Lanre Adeyemo","tldr":"Oral and maxillofacial surgeon who serves as Chief Medical Director of Lagos University Teaching Hospital, Nigeria's largest tertiary hospital.","route":"/people/wasiu-lanre-adeyemo/","kind":"person","round":true,"avatar":"person","sub":"Chief Medical Director · Lagos University Teaching Hospital","facets":{"kind":["Person"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"head and neck cancer","href":"/tagged/head-and-neck-cancer/","tip":"Every record tagged head and neck cancer."},{"label":"global oncology","href":"/tagged/global-oncology/","tip":"Every record tagged global oncology."}]},"sortKeys":{"year":0}},{"id":"wen-zhao-zhong","name":"Wen-Zhao Zhong","tldr":"Thoracic surgeon-scientist and hospital Vice President who led the ADJUVANT/CTONG1104 trial establishing adjuvant EGFR-TKI therapy in resected lung cancer.","route":"/people/wen-zhao-zhong/","kind":"person","round":true,"avatar":"person","sub":"Vice President and Party Standing Committee Member · Guangdong Provincial People's Hospital","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lung cancer","href":"/tagged/lung-cancer/","tip":"Every record tagged lung cancer."},{"label":"thoracic surgery","href":"/tagged/thoracic-surgery/","tip":"Every record tagged thoracic surgery."}]},"sortKeys":{"year":0}},{"id":"william-nelson","name":"William G. Nelson","tldr":"William Nelson is the long-time director of the Johns Hopkins cancer centre and a prostate cancer epigenetics researcher.","route":"/people/william-nelson/","kind":"person","round":true,"avatar":"person","sub":"Director, Sidney Kimmel Comprehensive Cancer Center · Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"prostate cancer","href":"/tagged/prostate-cancer/","tip":"Every record tagged prostate cancer."}]},"sortKeys":{"year":0}},{"id":"xiang-hua","name":"Xiang Hua","tldr":"Hospital president who leads Hunan Cancer Hospital, the provincial cancer hospital of Hunan and the affiliated cancer hospital of Central South University's Xiangya School of Medicine.","route":"/people/xiang-hua/","kind":"person","round":true,"avatar":"person","sub":"President (院长), Hunan Cancer Hospital · Hunan Cancer Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"yakubu-seidu-adam","name":"Yakubu Seidu Adam","tldr":"Consultant eye surgeon who has been Chief Executive of Korle Bu Teaching Hospital, Ghana's largest referral hospital, since May 2025.","route":"/people/yakubu-seidu-adam/","kind":"person","round":true,"avatar":"person","sub":"Chief Executive Officer of Korle Bu Teaching Hospital · Korle Bu Teaching Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"ophthalmology","href":"/tagged/ophthalmology/","tip":"Every record tagged ophthalmology."}]},"sortKeys":{"year":0}},{"id":"yasmine-belkaid","name":"Yasmine Belkaid","tldr":"Immunologist who leads the Institut Pasteur in Paris, having taken up its presidency in January 2024 after a long career at the US National Institutes of Health.","route":"/people/yasmine-belkaid/","kind":"person","logo":"/portraits/yasmine-belkaid.jpg","round":true,"avatar":"person","sub":"President (Director General) of the Institut Pasteur · Institut Pasteur","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"immunology","href":"/tagged/immunology/","tip":"Every record tagged immunology."}]},"sortKeys":{"year":0}},{"id":"yasuharu-nakashima","name":"Yasuharu Nakashima","tldr":"Orthopaedic surgeon who became Director of Kyushu University Hospital in Fukuoka in April 2026 after eight years as a vice director.","route":"/people/yasuharu-nakashima/","kind":"person","round":true,"avatar":"person","sub":"Hospital Director (病院長) of Kyushu University Hospital · Kyushu University Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"orthopaedics","href":"/tagged/orthopaedics/","tip":"Every record tagged orthopaedics."}]},"sortKeys":{"year":0}},{"id":"yasumasa-niwa","name":"Yasumasa Niwa","tldr":"Physician who leads Aichi Cancer Center Hospital, the 500-bed prefectural cancer hospital in Nagoya, Japan, as its hospital director.","route":"/people/yasumasa-niwa/","kind":"person","round":true,"avatar":"person","sub":"Hospital Director, Aichi Cancer Center Hospital · Aichi Cancer Center","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital","href":"/tagged/hospital/","tip":"Every record tagged hospital."}]},"sortKeys":{"year":0}},{"id":"yasuyuki-nasuhara","name":"Yasuyuki Nasuhara","tldr":"Hospital director who has led Hokkaido University Hospital, a large university teaching hospital in Sapporo, since April 2025.","route":"/people/yasuyuki-nasuhara/","kind":"person","round":true,"avatar":"person","sub":"Director of Hokkaido University Hospital · Hokkaido University Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"yongyut-sirivatanauksorn","name":"Yongyut Sirivatanauksorn","tldr":"Physician who directs Siriraj Hospital, Thailand's oldest and largest hospital and the teaching hospital of Mahidol University's Faculty of Medicine Siriraj Hospital.","route":"/people/yongyut-sirivatanauksorn/","kind":"person","round":true,"avatar":"person","sub":"Director of Siriraj Hospital · Siriraj Hospital, Mahidol University","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"university-hospital","href":"/tagged/university-hospital/","tip":"Every record tagged university-hospital."}]},"sortKeys":{"year":0}},{"id":"yu-jinming","name":"Yu Jinming","tldr":"Academician of the Chinese Academy of Engineering who is President of Shandong Cancer Hospital and Institute, the provincial cancer hospital in Jinan.","route":"/people/yu-jinming/","kind":"person","round":true,"avatar":"person","sub":"President (院长), Shandong Cancer Hospital and Institute · Shandong Cancer Hospital and Institute","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"yuqin-song","name":"Yuqin Song","tldr":"Lymphoma specialist and Vice President of Peking University Cancer Hospital.","route":"/people/yuqin-song/","kind":"person","round":true,"avatar":"person","sub":"Vice President · Peking University Cancer Hospital","facets":{"kind":["Person"],"cancers":["Diffuse large B-cell lymphoma","Follicular lymphoma","Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."},{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."}]},"sortKeys":{"year":0}},{"id":"zhang-shuyang","name":"Zhang Shuyang","tldr":"Physician who leads Peking Union Medical College Hospital, the flagship academic hospital of the Chinese Academy of Medical Sciences in Beijing.","route":"/people/zhang-shuyang/","kind":"person","round":true,"avatar":"person","sub":"President (院长), Peking Union Medical College Hospital, Beijing · Peking Union Medical College Hospital","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"hospital-management","href":"/tagged/hospital-management/","tip":"Every record tagged hospital-management."}]},"sortKeys":{"year":0}},{"id":"ziyu-li","name":"Ziyu Li","tldr":"Gastric cancer surgeon who serves as President of Peking University Cancer Hospital.","route":"/people/ziyu-li/","kind":"person","round":true,"avatar":"person","sub":"President and Deputy Party Secretary · Peking University Cancer Hospital","facets":{"kind":["Person"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"gastric cancer","href":"/tagged/gastric-cancer/","tip":"Every record tagged gastric cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}}]